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Radiation therapy for prostate cancer has evolved or time.  Intra-fractional motion of the prostate has been a 
clinical limitation in dose delivery.  Reduced margins can lead to less toxicity to critical structures and an 
overall reduction in the risk of secondary cancers.  Three models have been developed to predict prostate 
margins based on the first five fractions of treatment. 
 
An 8th order polynomial model is utilized with the 95% and 99% predictive lines indicating margins.  This 
approach is applied to 24 patients.  The maximum values as indicated by the predictive lines are used as the 
margins for the patient.  The resultant margins are then compared with the remaining 34 fractions of treatment 
to determine whether a model is acceptable for clinical treatment. 
 
The cumulative frequency distribution (CFD) is the second approach used in determining margins.  The 95% 
and 99% data points are used as the predictive margins.  The computed margins are then used to determin  if 
the model is acceptable.  A Bayesian model is the final approach.  A posterior distribution is computed by 
implementing a uniform prior along with a Gaussian l kelihood function.  The 95% and 99% points along the
distribution are utilized for margin determination. 
 
Treatment plans are developed comparing the model that is most accurate versus a standard margin set that is 
in clinical practice.  Individual margins derived by using the mathematical model varied significantly from 
patient to patient with ranges as follows (in mm): +x (1.5 to 2.5), -x (1.5 to 3.7), +y (1.5-5.4), -y (1.6 to 5.7), 
+z (1.5 to 4.2) and –z (1.5 to 4.6).  The percentage of time the prostate moved outside of the individual patient 
margins based on the model was 0.86 +/- 1.07, 2.56 +/- 3.65 and 4.37 +/- 4.24 respectively. 
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   Chapter 1 
Introduction 
1.0 Prostate Cancer Therapy 
Prostate cancer is one of the leading cancers diagnosed in men within the United States and is expected to 
affect 241,470 men of which 28,000 will die in 2012 (Siegel, 2011).  Now, more than ever, patients have a 
variety of treatment options.  These options include surgery, radiation therapy, brachytherapy, hormones and 
watchful waiting.  The field of radiation oncology has led the way in technical advancement with regards to 
treating prostate cancer.  Figure 1.1 represents a modern day linear accelerator.  In the early 1990s, prostate 
cancer radiation therapy generally consisted of a 4- ield (4 gantry angles) technique using standard cerrobend 
blocking (metal alloy material) around normal strucures in order to minimize collateral damage to surro nd 
tissue. This method was effective but due to limitations by the equipment, a significant portion of the normal 
tissue received significant dose. 
 
 
Figure 1.1 Varian TruBeam Linear Accelerator 
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The 4-field technique soon gave way to a 6-field technique that allowed slightly better normal tissue paring 
but still gave significant dose to surrounding tissue .  Around 2000, a new and more conformal technique 
called Intensity Modulated Radiotherapy (IMRT) was developed and quickly became the standard of care at 
many cancer centers around the United States.  IMRT uses computerized Multi-Leaf Collimators (MLC) made 
of tungsten leaves placed in front of the beams path within linear accelerators in order to modulate th  
radiation beam pathway as it traverses through targe  tissues and normal tissues.  In addition, better 
optimization algorithms were developed.  The combination of the use of MLCs and better optimization 
algorithms allowed for increasing conformal dose distributions around the prostate and resulted in sigificant 
sparing of surrounding tissue.  With such sharp dose gradients around the prostate, motion management 
became increasingly important and several Image Guided Radiotherapy Technologies (IGRT) also emerged 
simultaneously with the emergence of IMRT. 
 
IMRT was a new concept in radiation therapy planning that had never been undertaken before.  In conformal 
treatment planning, the physician draws the tumor, critical structures and blocks.  The physician then inputs 
the desired dose to be delivered and then, the dose calculation is displayed quantitatively for approval by the 
physician.  The physician can then change the blocking or relative radiation field weighting but has little other 
control over how much dose critical structures willreceive.  When utilizing IMRT, the process works the
opposite.  The algorithm utilizes inverse optimization in order to calculate dose.  The physician still contours 
the critical structures and tumor but can now tell the computer how much dose to deliver to each structu e, 
including the prostate.  The algorithm works backwards in order to deliver the dose as prescribed to all 
structures.  This process results in a significant number of “modulations” of the beam in order to achieve the 
desired results.  In what used to be delivered in 6 ports (gantry angles), is now delivered in effectively 100-120 
ports.  The advent of IMRT allowed dose escalation in prostate therapy.  Most clinicians using the standard 4/6 
port technique delivered doses around 66 Gy to the prostate.  Once the method of delivery switched to IMRT, 
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dose levels escalated to 78-81 Gy based on clinical evidence that increasing radiation doses to the prostate 
resulted in improved biochemical relapse free survival for patients (Zietman, 2005). 
 
Once the use of IMRT became widespread, the issue of patient positioning became a significant issue in the 
oncology field.  With such high modulation and the increase in prostate dose as a result, accurately positioning 
the patient became paramount.  Standard practice in th  radiation field included taking x-ray films weekly.  
This method utilized boney anatomy as an indicator if the patient was positioned correctly during treament.  
Since most patients being treated have tumors that are soft tissue, weekly port films are inadequate as soft 
tissue is not well visualized with such devices.  
 
1.1 The Need for IGRT in IMRT Treatments 
The increase in dose and beam modulation requires improved tumor motion management and led to the 
development of IGRT devices, which focus on soft tissue alignment instead of bony tissue registration.  IGRT 
utilizes a number of different methods in order to determine the location of the prostate.  One of the irst 
methods implemented in IGRT was ultrasound.  Prior to each daily radiation treatment delivery (i.e. fraction of 
the total dose being delivered), the patient has an abdominal ultrasound study, which allows the cliniian to 
accurately locate the prostate.  The patient is then s ifted into the correct position prior to treatment.  This 
method has proven to be effective in most cases but has drawbacks including poor ultrasound images, not 
accounting for intra-fractional motion as well as position deformation with the ultrasound probe.  An example 





Figure 1.2 Ultrasound System for Prostate Localization 
 
The next development involved placing fiducial markers (small metallic objects) in the prostate for 
localization.  A total of 3 gold fiducial markers (~ 7.5 mm in length) are inserted into the prostate prior to 
simulation for treatment (Figure 1.3).  These markers are then tracked prior to each treatment.  Computer 
software allows the alignment of the markers with the original CT scan in order to properly position the patient 
for treatment.  This method has one significant limitation in that it is unable to track intra-fraction motion.  The 
Calypso system has introduced a newer concept and uses 3 implanted radio transponders within the prostate 
that emit a radiofrequency of 10 Hz during radiation treatment delivery.  These transponders allow the 
clinician to track prostate motion real time during an entire treatment session.  Real time tracking data has 
shown that intra-fraction prostate motion can be very significant (Langen, 2008).  Much like the fiducial 
markers, these transponders are placed prior to simulation.  Once the patient is positioned on the table, these 




Figure 1.3 Gold Fiducial Markers 
 
 
Figure 1.4 Calypso System 
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the event that the transponder falls outside an acceptable range.  The following figure represents a Calypso 
imaging system.  With the addition of IMRT along with IGRT, there has been a push in the clinical 
environment to reduce margins in order to minimize toxicity to critical structures (Gill, 2011).  In prostate 
cancer, these critical structures include the rectum, bladder, penile bulb and femoral heads.  Althoug all 
critical structures have limitations with respect to dose, the rectum and bladder are key in this process and tend 
to weigh more in clinical evaluation.  One of the limiting factors in dose escalation to the prostate is he dose to 
these aforementioned structures.  In the early history of radiation therapy, it was not uncommon to see 10 mm 
margins for the prostate in all directions with a 7.5 mm posterior border along the rectal wall.  There are still a 
number of cancer centers that use these margins.  Not only does this limit how high a dose can be given to the 
prostate, it also increases the potential for short term and long-term side effects to surrounding tissue (Gill, 
2011).  Normal tissue receiving dose 20-30 mm outside of the field is at an increased risk of complications. 
 
There are protocols for prostate margins that have been greatly reduced from the days prior to IGRT.  One 
clinical model is a 6 mm margin in all directions and a 4 mm margin posteriorly near the prostate/rectum 
interface.  In addition, there is at least one model that suggests 2 mm margins all around may be possible with 
the use of real-time intra-fraction prostate tracking (Haise, 2008).  The commonality with all of these models is 
that they assume margins are uniform across all patients and all related prostate motion will fall in between 
these margins during treatment delivery.  In addition, these margins do not take into account the patint 
specific prostate motion, which is not currently fully understood. Clinicians continue to debate if prostate 
motion varies from patient to patient and if one can individualize and develop patient specific treatment 
margins based on individualized patterns of prostate motion.  Thus, clinicians continue to use a wide range of 




1.2 Patient Prostate Tracking Data 
The Calypso system uses three radio transponders to cap ure prostate motion.  These transponders measure 
three vector coordinates (X,Y,Z) as a function of time (t).  These transponders are placed in the prostate prior 
to simulation and in no set pattern.  Figure 1.3 is an anatomical rendering of how the transponders ar 
positioned in a typical patient.  These markers are specially coated to reduce movement over the course of 
therapy.  In Figure 1.4, the collection plate is poiti ned over the patient during their treatment delivery.  The 
purpose of the collection plate is to receive the information from the transponders.  The material on the plate is 
radiolucent in order to reduce the potential for beam attenuation.  The plate remains in position for the entire 
period of treatment.  The radio transponders transmit data at a rate of 10 Hz.  The collection plate receives the 
transponder coordinate values during the entire length of the treatment.  These values are transmitted in raw 
vector components.  In order to analyze the motion, hese data coordinates are then converted into the centroid 
or geometric center of the transponders.  The following formula is utilized for this conversion. 
 
 






















       
 
Figure 1.5 Calypso Transponders in Prostate Gland 
 
 
Figure 1.6 Collection Plate Positioning During Treatment 
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Where (X,Y,Z) represent the corresponding vector comp nent of the specific transponder.  By converting he 
data into the centroid, any noise in the set can be minimized.  The collection process will yield approximately 
50,000 data points to analyze since it is captured at a 10 Hz frequency.  On average, a treatment session for a 
patient will last from 6-12 minutes.  The large variability in the time is related to the amount of interruptions 
that are necessary in order to reposition the patient (Howard, 2010), and the type of linear accelerator that is 
used during treatment delivery.  In the initial work with Calypso, a threshold was set at 5 mm for 30 seconds.  
This corresponds to the centroid having a deviation of 5 mm lasting greater than 30 seconds in any one 
direction.  When this occurs the beam is stopped and the patient is repositioned so that the transponders and the 
prostate can be realigned to the original isocenter (0,0,0).  Once this is achieved, the radiation beam is restarted 
and the treatment session is either completed or interrupted again if the time and distance threshold of 5 mm 
lasting greater than 30 seconds is exceeded.  Aftera p iod of time, it was determined that the criteria could be 
tightened.  Clinicians decided on criteria that resulted in a reduced prostate motion cut off of only 3 mm.  This 
did not result in delays of treatment delivery to patients and thus was considered clinically acceptable.  All of 
the current patient files analyzed within this work follow the 3mm/30 sec intervention limits.   
 
1.3 Scope of Research 
Radiation therapy treatment of prostate cancer is centered on a population based model for treatment margins 
(Van Herk, 2000).  All patients are assigned standard margins as determined by the radiation oncologist.  The 
uniform margin approach does not account for a variety of biological and physiological functions that v ry 
from patient to patient (Khan, 2012).  In addition, it has been shown that prostate motion is patient specific and 
not uniform as previously thought (Howard, 2012).  The possibility of patient specific margins has the 
potential to introduce significant dose sparing to critical structures while maintaining adequate coverag  of the 
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prostate gland.  In addition, the potential to reduce the overall risk of secondary cancers by reducing radiation 
dose to surrounding structures is a significant concer  in the oncology community (Kleinerman, 2005).   
 
This research will determine if prostate motion is predictable and if so, could one develop differential 
treatment margins for each patient based on patient specific patterns of prostate motion.  The first step is to 
develop three different statistical models that model motion.  These models include the Polynomial, 
Cumulative Frequency Distribution and a Bayesian approach.  A model will be developed for each coordinate 
component (X,Y,Z).  Using data from the first five fractions (i.e. model building), each model will then be 
tested using new data that the model has not previously seen (model validation step).  Initial work on seven 
patients showed that five fractions are effective in developing a model (Howard, 2010).  
 
The available data consists of 24 patients receiving radiation therapy at the Cleveland Clinic.  This data is 
made available all patient identifiers removed in Excel format.  A total of 31 patients were available for 
analysis.  Once this data was received and reviewed, it was determined that only 24 were suitable for 
modeling.  7 of the 31 patients did not qualify for analysis as they had limited prostate tracking data that was 
not representative of a full course of IMRT. The patients reviewed in this study received a standard course of 
fractionated radiation therapy lasting for about 39 fractions depending on various clinical factors and the 
prescribed radiation dose.  The prostate motion tracking data was collected with all patient identifiers being 
removed due to HIPPA compliance issues.  The daily treatment process, setup and positioning follow standard 




A comparison of each model will be made to determine which model is best at predicting motion.  Once the 
preferred model is determined, it will be compared against two other clinical models.  These models are the 2 
mm model (Haise, 2008) and a clinically derived 6/4 mm model, which is based on clinical expertise.  This 
comparison will be accomplished by comparing the predictive margins as determined by the models based on 
data from the first five fractions and assess their ability to predict future prostate motion for the remaining 34 
fractions by scoring the percentage of prostate vector data points falling outside of the predicted margins.  
Criteria for the evaluating the performance of each model will be given in Chapter 2. 
 
The preferred predictive model will then be compared with the 6/4 mm model in order to determine the eff ct 
on treatment planning.  The Dose Volume Histogram (DVH) will be the method of evaluation to see if the
predicted margins can reduce dose to the bladder and ectum.  A treatment plan will be developed with the
standard margins and then compared with an identical treatment plan developed with the predictive margins.  
This is accomplished by using a standard CT data set for a patient.  A plan using each margin recipe will be 
developed based on the same anatomy.  This will allow for a direct comparison of results.  The DVH of the
prostate, rectum and bladder will be evaluated at the dose values of 70 Gy, 50 Gy and 20 Gy.  This comparison 





Methods and Theory 
2.0 Statistical Approach 
As outlined in Chapter 1, there are three approaches taken in determining the predictive margins for patient 
treatments. In clinical radiation therapy, margins are assigned around critical structures in order to include 
gross as well as microscopic disease (i.e. disease th t is outside of the prostate gland).  This volume is referred 
to as the Planned Tumor Volume (PTV).  These margins are constant and cannot be varied during the course of 
a treatment delivery.  With this constraint in mind, the developed model must be able to make the margins as 
small as possible and still satisfy the criteria required for the treatment.  The model must also estimate margins 
that are not too large.  If the predictive margins are too large then the clinical impact of reducing standard 
margins is minimized or eliminated.  
 
With these issues in mind, three separate models have been developed to predict patient specific margins for 
the series of patients utilized in this study.  These models are the Polynomial, Cumulative Frequency 
Distribution (CFD) and Bayesian approaches.  The details of the models and their application to this re earch 







Table 2.1 Criteria for Model Evaluation 








The basis for these values is determined by using current clinical standards for estimating accuracy in dose 
delivery (Bezjak, 2009).  Radiation Therapy Oncology Group (RTOG) which is a national cooperative group 
funded by the National Cancer Institute (NCI), requires that 95% of the prescribed dose cover the PTV.  his 
range defines the acceptable response of the model.  Th  marginal range is established based on RTOG 
requirements that 99% of the PTV receive a minimum of 90% of the prescribed dose.  When scoring a model, 
the assumption is that when any part of the prostate falls outside of the margin, it is not receiving the
prescribed dose.  This is valid when using 3-D techniques previously described.  However, the use of IMRT 
reduces the probability of this occurring.  The modulation of the radiation beam delivers dose in small fields 
within the PTV.  This results in the potential for dose being delivered to the prostate even when a portion of 
the prostate falls outside of the margins.  The impact of this effect is not evaluated in this research, thus the 




In the instance where the model predicts clinical mrgins that are not deliverable (i.e. too small), a threshold 
must be established within the model.  This case ari s when very little motion is displayed across the data 
sets. Routine radiation therapy delivery in the clini al setting has limitations such as setup error, laser 
alignment and immobilization.  For the purpose of this research, this minimum margin will be set at 1.5 mm.  
Whenever the model determines margins less than 1.5 mm, the default of 1.5 mm will be used.  This represents 
a small margin relative to current clinical standards that can still be delivered clinically.  Future work might 
determine this value to be higher or lower but additional study is required and will be discussed in the chapter 
dealing with future work. 
 
2.1 Beam Modeling 
In order to deliver accurate dose with small fields, proper beam modeling is required.  The predictive 
margin approach utilizes small margins and thus increases the need for accurate modeling.  The modeling 
process is divided into four steps.  The first section focuses on the beam spectrum.  The energy spectrum 
defines the number of photons and associated energis in the range.  There are sets of spectra data that 
have been published that allows the physicist to opimize the measured data.  This process is critical in 
that the calculation of dose is dependent upon the modeled beam energy.  The following figure represents 





Figure 2.1 Beam Spectrum for Photons 
 
Once the beam spectrum is modeled, the electron contami ation must be added to the beam in order to 
account for the scatter effects from the linear accelerator head.  This is accomplished by modeling the 
contamination as a modified exponential curve.  At shallow depths, the dose is linear so as not to deliver 
excessive dose to the skin surface.   
 
The next step in the modeling process is developing the in-field parameters.  The flattening filter 
attenuation and off-axis softening are the two prima y effects seen in field.  The flattening filter 
attenuation has two effects on the beam.  First, it changes the relative magnitude of the photon energy as a 
function of off-axis distance.  In addition, it softens the beam as a function of off-axis distance.  The off 
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W is the defined as the spectral weight for bin “I” which has an effective energy Ei.  Theta is the off-axis 
angle.  It is calculated using the following equation. 
 








a tanθ      (2.2) 
 
The off-axis distance is the distance between the central axis and the point of measurement that is 
orthogonal to the beam.  As you increase the off-axis softening parameter, there is an increase in the horns 
associated with the profile of the beam.  This is more pronounced near the surface of the beam. 
 
Once the in-field parameters are modeled, the out of field parameters are determined.  The out of field 
parameters have an impact in determining accurate dos elivery to patients.  There are two primary 
components of the out of field model.  The first factor is the effective source size parameter.  The primary 
effect of source size is the modeling of the penumbra.  This is accomplished by blurring the incident 
fluence model.  The blurring kernel is modeled as a Gaussian function with the FWHM modeled as the 
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effective source size.  If the effective source siz is increased, the shoulders and base of the profile are 
more round.  Decreasing the source size makes the profile more square.   
 
The second parameter for out of field modeling is the flattening filter scatter source (FFSS).  The 
flattening filter changes the shape of the primary beam but also is a source of secondary radiation.  The 
FFSS models the scatter from the flattening filter.  This effect is primarily seen in the tails of the 
distribution.  The scatter is modeled with a Gaussian curve.  There are two controls that can change this 
curve.  The Gaussian height parameter determines the fraction of energy along the central axis that is due 
to scatter from the flattening filter.  The Gaussian width parameter determines the width of the curve that 
is used to model the FFSS.  Once the photon beam is properly modeled, the dose using the convolution 
algorithm can be calculated.  The method of dose calculation is discussed in the following section. 
 
2.1.1 Convolution Algorithm 
Once the beam has been accurately modeled, it is necessary to calculate the dose at a given point in the patient. 
This is accomplished by using the convolution algorithm.  This approach uses several components in order to 
calculate dose.  The convolution algorithm is given in the following equation. 
 
     
         (2.3) 
 




The factors in the equation above will be defined sparately.  It is important to note that the above equation 
shows no energy dependence.  Each parameter has an energy dependence but the equation is a simplified 
version of the convolution algorithm.  The energy has been integrated out over the range of spectral energies as 
determined in the modeling process. 
 
The first factor in the integral is 
µ
ρ ′ 
r ( ), which is defined as the mass attenuation coefficint.  This 
coefficient is defined as the amount of energy removed from the primary radiation fluence per unit mass.  
The density of the patient determines the value of this spatially dependent factor.  The primary energy 
fluence Ψ ′ r ( ) represents the photons per unit area.  This factor represents the photon energy at a given 
point.  In addition, the integral over the range of spatial locations gives the total photons in the volume 
irradiated.  The product of the mass attenuation coeffi ient and the energy fluence is the referred to as the 
total energy released per unit mass (TERMA).  TERMA is defined as the total amount of radiation at 
point ′ r ( ) that is available for deposition in the patient. 
 
The third factor is the convolution kernelK r − ′ r ( ).  This is a polyenergetic dose-spread kernel.  The
values are determined by averaging the local beam spectrum of the radiation field.  The photon energy 
range is determined in the modeling process by using the correct energy spectrum.  The spectrum is 
spatially dependent so the kernel represents the energi s at a given location in the patient.  The 
convolution algorithm is the fundamental method with which dose at any given point in the patient is 




2.2 Polynomial Model 
The initial model implemented in this research is the polynomial (Ott, 1988).  The reasoning for this approach 
is that the polynomial is well understood, with well-defined mathematical properties. The computational 
process is straightforward and can be accomplished through a number of statistical programs.  Polynomials 
have different orders and take the form in equation 2.4. 
 
                                  d = an t
n + an −1t
n −1 + ...+ a2t
2 + a1t
1 + a0                                (2.4) 
                                                                                                                                                                                                     
In the equation above, the dependent variable is the time (t) and the dependent variable is position (d). The 
above equation when plotted will generate a graph of motion over a given period of time.  The coefficients of 
the polynomial can be determined taking the derivative of the polynomial at x0. The variable x0 is defined in 
equation 2.5. 




                                                                    (2.5) 
 
The fit of the equation is through the center portion of the data points.  Due to the motion of the prostate, there 
is a scattering of the points.  This reduces the effectiveness of this model if you consider only the fit quation.  
In order to account for the variations over the range of data, a prediction line is applied to the polyn mial 
equation.    The commercial software Sigma Plot version 11.2 is used for this model development.  Figure 2.1 




Figure 2.2 Displacement vs. Time 
 
The center line on Figure 2.1 is representative of the polynomial fit and the two encompassing lines represent 
the 99% predictive lines applied to the data.  Qualitatively it can be noted that the maximum and minium 
points on the predictive lines are reactive to changes in the data pattern.  These points are more pronounced 
when using a higher order polynomial model.  Once it was determined that a polynomial model would be an 
appropriate choice for the initial work, determining the order is the next step. 
 
Lower order polynomials are most often utilized in data analysis.  However, in this case, a higher order 
polynomial might give significant improvement in the data analysis.  Initially, 3rd and 4th order polynomials 
were analyzed.  Due to the lower order, these polynomials have less of an ability to react to changes in the 
data.  These changes include rectal gas along with other biological effects that result in quick displacement of 
21 
 
the prostate.  These deviations which are generally on the order to 5 to 10 mm in magnitude can occur ove just 
a few seconds or last for up to one minute.  The lower order functions are unable to effectively model th  
inflection points during these changes.  However, it was determined through several iterations of trial and error 
that higher order functions were able to better capture some of these deviations.  Thus, an 8th order polynomial 
proved to be the most effective approach. 
 
In order to determine where a specific percentage of the data values fall, the predictive lines are utilized.  The 
predictive line can be defined as the range where data values will fall within for repeated measurements.  In 
this research, the maximum and minimum points of the predictive lines, in both the positive and negative axis 
for each of the three models is used for clinical mrgins. In radiation treatments, margins cannot be varied 
during delivery, so the maximum point is the appropriate value to use.  In addition, using the maximum point 
of along the predictive line will give an extra margin to account for potential larger displacements i future 
treatment sessions.  This is demonstrated in Figure 2.1.  The formula for calculating the predictive line is given 
in equation 2.6 (SigmaPlot, 2009). 
 
                                                                                  (2.6) 
 
The variable yo represents the 8
th degree polynomial model used in fitting the data for this model.  The 
variables n is representative of the number of datapoints and p is the degree of the polynomial fit.  The t value 
is a constant that is computed with a sixth order rational polynomial approximation (Sahai, 1974).  The 
























                                                     (2.7) 
 
The variable X0 is defined as the (p+1) and the X is defined as the n*(p+1) matrix.  They are defined in the 
following equations 2.8 and 2.9 (Draper, 1981). 
 
                                                   X o
′ = 1 x0 x0
2 . x0
p[ ]                                              (2.8) 
 
                                                                                                     (2.9) 
 
The variable x0 is defined in equation 2.5.  The xn
p  variable in equation 2.9 is associated with the 
corresponding polynomial.  The polynomial fit is done to the cumulative set of data.  The first five fractions 
are composed of five individual sets of data representing different days of treatment.  There is a natural 
statistical variation over this period of time.  Byanalyzing the five individual sets as one cumulative set, a 
better model can be developed. 
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2.3 Cumulative Frequency Distribution (CFD) 
The polynomial model is a statistical model that can be utilized in predicting margins with respect to pr state 
motion.  The polynomial approach takes data supplied by the user to determine coefficients in an equation that 
is then used to predict motion.  The CFD model uses a different approach for margin prediction.  Unlike the 
polynomial model, there is no mathematical model usd in this approach.  The data for the first five fractions is 
used to predict margins.  
 
The CFD is a method that is straightforward and offers a different approach as seen with the polynomial 
approach.  The cumulative probability for the first five fractions is ranked from lowest to highest in value 
(Tamhane, 2000).  This can be seen in equation 2.10.
 
Pc = Ri / (N + 1)                                                      (2.10)            
 
Ri represents the position of the centroid at a given poi t.  The (N+1) is the sampling number which is defined 
as the total number of points in the population of data. Pc is the ratio of the rank number and total number of 
data points.   The margins are then determined by utilizing the 95% and 99% data points respectively.  This 
method is a CFD that determines how much time the centroid spends at specified distances from the zero 
position.  There are limitations to this method.  As previously mentioned, the assumption is that all future 
motion will fall within the range of the first five fractions.  This might not be realistic in most cases and thus 




In addition, depending on the size of the displacements that occur in every patient, the model may or may not 
be more accurate.  A poor sampling of data over the first five fractions could lead to incorrect margins.  As 
with the polynomial model, the 95% and 99% values ar  used in order to determine the clinical treatment 
margins. 
 
The following figure is representative of a CFD dataset which is made up of the first five fractions of 
treatment.  The graph is skewed in the negative direction.  This shows for the given patient and vector m del, 
there is a preference for the prostate to have a neg tiv  deflection during this time series.  The units on the x-
axis are in cm and indicated displacement.  The model developed from this approach will show a significant 
variation in margins within the (+/-) directions. 
 
 
Figure 2.3 Cumulative Probability Distribution 
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2.4 Bayesian Model 
In the previous sections, the polynomial model and CFD were discussed in detail.  In order to validate these 
approaches and to determine if there is a better model available, the Bayesian approach was undertaken.  
Classical statistics is commonly used in research studies throughout all scientific fields.  The Bayesian method 
is different yet offers comparable results with respect to the classical approach.  The key advantage in 
Bayesian analysis is that it is possible to update information that is either learned or gathered.  Updating allows 
the model to implement previously determined information into its calculation. This is accomplished by 
incorporating an informative prior into the posterior distribution.  The prior can either be a constant or a 
distribution that is representative of previously gathered data.  This is described by Bayes Theorem (Bolstad, 
2007).   
 
There are fundamental differences between the classi al statistics and the Bayesian approach.  Most comm nly 
noted is what is known as Bayes Theorem.  This theorem is the basis for the Bayesian approach and a 
fundamental understanding is necessary in order to implement this statistical method fully.  The basis for 
Bayesian analysis is that given knowledge about a given situation or event, how much should that knowledge 
affect the predicted outcome of a future event.  Figure 2.4 shows the impact that an informative prior can make 
on the data analysis.  Even with this potential impact, choosing a non-informative prior can be beneficial as 
well.  This is evident in that choosing the wrong prior or weighting information improperly in the prio  can 
give rise to an inaccurate posterior density.  This can lead to poor results.  Careful consideration needs to be 
made if using an informative prior.  Determining what data, how much to weight it and the proper functio  to 
model it with are all considerations.  The use of anon-informative prior assigns equal weighting to previous 





Figure 2.4 Graph of Posterior, Likelihood and Prior 
 
The prior will be discussed in detail in the next section.  Equation 2.11 is the basis for Bayesian analysis.  This 
equation shows the relationship between the probability of A and B.  Using the conditional probability of B 
given A and A given B.   
 






BAP =                                                    (2.11) 
 
The variable P(A) represents the prior.  The value P(B/A)  represents the likelihood distribution for the data 
set.  The choice for the likelihood function is important when determining the model that will best fit he data.    




2.4.1 Posterior Distribution 
The posterior distribution is an acceptable approach in developing predictive margins.  The definition f the 
posterior distribution is the cumulative knowledge about all uncertain parameters.  In this case it is the location 
of the prostate at any given point in time.  This definition also includes unobserved and potential data as well.  
This is particularly important since we are predicting future motion based on multiple sets of data.   
 
The prior can be an important component in the Bayesi n approach.  It has two basic forms, informative and 
non-informative.  The non-informative approach assumes no information is known and its value or effect 
defaults to unity.  This is a preferred method if very little is known about the data prior to analysis.  However, 
choosing a non-informative prior limits the effectiveness of the posterior distribution if additional information 
is available.  In this research, P(A)= 1.   
 
The informative prior is a valuable tool in determining a more accurate posterior distribution (Winkler, 2003).  
There are a number of methods used in informative priors including conjugate and joint priors.  The prmise 
behind using this approach is that when prior information is known about the data set, it can be incorporated 
into the likelihood to yield better results.  The mathematical issue with this approach is that the informed prior 
can skew datasets depending on how the data is obtained nd how heavy it is weighted in the calculation.  Its 
function is to supply information that may be available about a particular variable.  This information often can 
lead to more finite results and thus reduce the uncrtainty about the distribution. 
 
In the case of this research, a non-informative prior is utilized.  The reasoning behind this approach is two-fold.  
First, in the clinical world of medical physics, classical statistics dominates the field of study.  The vast 
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majority of all research is conducted utilizing this approach.  Incorporating a prior that provides little to no 
influence on the likelihood distribution allows for a wider clinical acceptance of this work.  Second, there is a 
debate on how much prior information is actually know .  Determining whether data gathered from other 
patients is considered prior information would need to be determined.  More discussion on this topic will 
appear in the future research chapter of this dissertation. 
 
The second factor of the posterior distribution is the likelihood function.  The likelihood consists of a function 
that best models the datasets being analyzed.  Throug  previous research (Khan, 2008), it has been shown that 
prostate motion is best described by a Gaussian distribution.  With this in mind, it was determined tha  a 
Gaussian function is best suited to model the patient data sets (Ott, 1988).  See equation 2.12. 
 










e                                                        (2.12) 
 
Where 
2σ is the variance and µ is the mean of the dataset.  The standard deviation (σ) is also factored into the 
function outside the exponential.  The Gaussian functio  can be solved through an iterative process.  The
variable (x) represents the prostate displacement at any given point in time.  The other parameters are 
computed based on the available data for the first five fractions of each patient.   
 
The mathematical process used in the Bayesian approch involves the following steps.  The first five fractions 
of data are taken for a specific patient.  The mean, v riance and standard deviation are calculated and entered 
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into the Gaussian function.  In order to determine the range displacements that the prostate has over the patient 
population, a review of the entire 24 patients has been done.  The vast majority of all patients will fall in the +5 
to -5 mm displacement range.  For the cases where tis range does not encompass prostate motion for a 
particular patient, the range will be increased to account for the increase in motion.  The Gaussian function is 
then computed over this range and normalized to the maximum point in order to generate the posterior 




Figure 2.5 Posterior Distribution  
 
The analysis is performed by taking the 95% and 99%data points in order to determine patient specific 
margins.  This figure models only one vector component of a particular patient.  In order to generate all the 




This approach will be compared to results obtained utilizing the polynomial model and the cumulative 
frequency distribution (CFD).  The Bayesian model is a statistical approach that is useful in predicting 
treatment margins based on prostate displacement ovr the first five fractions.  By analyzing multiple models, 
the potential to develop accurate patient specific margins is increased. 
 
 
2.5 Correlation Analysis 
The three statistical approaches presented here are useful in developing a model for predicting prostate motion.  
What the models do not do is determine why motion might be patient specific or what might lead to motion 
changes in a given model.  In order to better understand the factors affecting prostate motion, the data will be 
analyzed and a correlation analysis will be done on several patients.  This analysis is not meant to de ermine 
how all the physiological factors affect motion, rather this is meant to determine whether there is a correlation 
of motion across different vector models for a given patient or does each vector’s motion pattern for a patient 
operate independently of another.  This might be helpful in determining if one vector needs a uniform model 
across all patients or whether when a model fails, the reasoning behind it.   
 
First, it is necessary to define how this analysis will be done.  The most straightforward method to performing 
a correlation analysis of the data is the Pearson coeffi ient (Ott, 1988).  The basic description of the Pearson 
coefficient is that it measures the overall strength of linear dependence between two variables.  In the case of 
this research, the analysis involves the X / Y vector, X / Z vector and the Y / Z vector dependence.  The












= ∑                                                    (2.13) 
 
Equation 2.13 can be defined as the co-variation of x and y divided by the unique variation in x and the unique 
variation in y.  The variable xi is time and yi is position.  The coefficient is a measure of how much the 
variables vary together as compared to how much they vary on an individual basis. 
 
The Pearson coefficient can range in value from -1 to +1.  If the coefficient has a value of 0, then the data 
series are considered to have no linear relationship or correlation.  The closer the value comes to unity, the 
stronger the correlation exists between data sets.  Al hough the Pearson coefficient does not give a full picture 
of the data, i.e. degree of dependence between the two sets of variables it is an effective tool in determining a 
relationship between data sets.  Table 2.2 outlines th  values of the Pearson coefficient and how theyar  










Table 2.2 Correlation Values 
Correlation Positive Negative 
Poor 0-0.2 -0.2-0 
Fair 0.2-0.4 -0.2-(-0.4) 
Moderate 0.4-0.6 -0.4-(-0.6) 
Strong 0.6-0.8 -0.6-(-0.8) 
Near Perfect >0.8 >-0.8 
 
 
The values listed in the table above are just estimates.  There are no definitive numbers that are applic ble in 
all cases.  These values merely provide guidance in how to interpret the Pearson coefficient.  Other analysis 
such as the modeling results will be helpful in determining the correlation between the various vector 
components.   
 
In order to provide a complete analysis of the data, the p-value should be evaluated along with the Pearson 
coefficient.  The p-value determines whether the probability of the data differing in the method presented 
happened by chance or is of statistical significance.  The lower the p-value, the chance for a random happening 
is decreased.  A threshold is set; below this threshold, the data is considered significant.  This value varies 
between researchers and there is no definitive number but in the case of this research, it will be set to .01. 
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The correlation analysis will be done on three patients.  The analysis will first be done on the five ractions 
used to determine the predictive margins.  Then, an analysis will be completed on the remaining 34 fractions 
that are used in determining the success of the model.  Comparing the results of the first five fractions versus 
the remaining fractions could provide insight to why a model might pass or fail.  Also, this analysis m ght 
allow a better understanding of whether a particular vector component (X,Y,Z) is completely independent of 
other vectors.  This is helpful in determining if a universal margin approach is warranted.  In addition, this 
analysis will help in determining whether there is a correlation between any two vector components (Khan, 
2012).  This can result in a better understanding of prostate motion as well as better methods in developing 




















3.0 Overview of Results 
The results discussion will be divided into several sections in order to facilitate discussion and analysis of the 
different models.  The first section will focus on the Polynomial approach.  The second section will focus on 
the Cumulative Frequency Distribution and then followed by the Bayesian model.  Each section will discus  
the general methods of each model, clinical margins enerated and the overall performance of the model 
versus other clinically accepted approaches. 
 
The following section will compare and contrast all three predictive models.  Included in this comparison will 
be a recommendation of the best model for clinical implementation.  The recommendation will be based on 
model performance as determined by Table 2.1 and the associated clinical margin evaluation.  There will be a 
final section dedicated to reviewing the correlation analysis.  The correlation analysis will be discussed for 
several patients and any findings or recommendations will be addressed. 
 
3.1 The Polynomial Model 
The Polynomial approach as described in Chapter 2 has been applied to the group of 24 patients that were
obtained for this research.  Tables 3.1 and 3.2 summarize the margins that were developed using the 95% and 




Table 3.1 Clinical margins (in millimeters) for the Polynomial model utilizing the 95% predictive line. 
Patient +X -X +Y -Y +Z -Z 
101 1.5 1.5 2.4 2.9 2.7 3 
102 1.5 3 1.5 1.5 2 2.1 
103 2 1.5 3.5 5.5 2.5 5.2 
106 1.5 1.5 1.6 3.1 2 3.5 
108 1.5 1.5 5.5 2 4.5 1.8 
109 1.5 1.5 2.5 2.3 3.5 3.2 
110 1.6 1.5 3 1.7 2.9 1.9 
111 1.5 1.5 1.5 3.5 1.5 1.9 
112 1.5 1.5 2.5 3.1 5 3 
113 2.1 1.5 1.5 1.5 1.5 1.5 
114 1.5 1.5 3 1.6 2.4 1.9 
115 1.5 1.5 1.5 3.5 1.8 3.2 
116 1.8 1.5 2.1 3.1 3.2 4 
117 1.5 1.5 5 5.7 4.3 4 
118 1.5 1.5 1.5 2.7 1.6 3 
119 1.5 1.8 1.5 1.8 2.8 3.3 
120 1.5 1.5 2.4 2.4 2.6 3 
123 1.9 2.2 3.5 2.7 1.5 2.7 
124 1.5 1.5 1.5 1.5 1.5 2.3 
125 1.9 1.5 3.4 2.9 3.1 2.4 
126 1.5 1.5 2 2.5 1.5 2.3 
129 1.5 1.5 2.3 1.5 1.9 2.5 
130 2.2 1.5 2.4 2.8 2.3 3.1 
131 1.9 1.5 1.8 1.5 3.4 1.8 
Mean 1.62 1.60 2.47 2.64 2.57 2.77 
S. Dev 




Table 3.2 Clinical margins (in millimeters) for the Polynomial model utilizing the 99% predictive line. 
Patient +X -X +Y -Y +Z -Z 
101 1.5 1.5 3.4 3 3.4 3.4 
102 1.6 3.5 1.5 1.7 2.3 2.5 
103 2.2 1.5 4.2 6.3 3.1 5.8 
106 1.5 1.5 2.1 3.7 2.7 4.3 
108 1.5 1.5 6 2.6 4.9 2.3 
109 1.5 1.5 3.2 2.9 4.3 4 
110 1.7 1.5 3.5 2.2 3.6 2.4 
111 1.5 1.5 2 1.9 1.6 2.2 
112 1.5 1.5 3.2 3.6 5.8 3.8 
113 1.5 2.4 1.5 1.5 1.5 3.5 
114 1.5 1.5 3.5 2.1 3.2 2.4 
115 1.5 1.5 1.9 3.8 2.3 3.8 
116 2.1 1.5 2.5 3.6 4 4.7 
117 1.5 1.5 6.4 7 5.2 4.9 
118 1.5 1.5 1.5 3.1 2 3.5 
119 1.5 2 1.5 2.1 3.4 4 
120 1.5 1.5 2.9 3 3.4 3.8 
123 2.4 2.8 4.4 3.3 1.5 2.8 
124 1.5 1.5 1.5 1.5 1.5 2.4 
125 2.1 1.5 4.1 3.7 3.6 2.4 
126 1.7 1.7 2.3 2.8 1.8 2.5 
129 1.5 1.5 2.7 2.1 1.9 2.6 
130 2.3 1.5 2.9 3.3 2.9 3.8 
131 2 1.7 2.3 1.7 3.5 2.3 
Mean 1.64 1.80 3.03 3.12 2.95 3.47 
S. Dev 




As previously discussed, a 95% and 99% predictive line is applied to the 8th order fit.  These lines are used in 
determining the clinical margins.  Since margins are not adjustable during the actual treatment delivery, only 
the maximums in either the positive or negative dirct on will be used in defining the clinical margins.  
Included in the summary of the patients is the associated mean and standard deviation for the entire population.  
This will be discussed in detail for each vector model.  The corresponding coefficients to the 8th order fit are 
available in the appendix for review. 
 
3.1.1 Polynomial, X-model 
The X-vector represents lateral motion of the prostate.  In general, this direction has less movement than the 
other vectors.  Based on the results in the previous tables, the mean for the 95% prediction line is 1.62 for the 
(+X) direction and 1.6 for the (–X) direction.  The corresponding standard deviations are 0.23 and 0.33 
respectively.  This is indicative of data that has very little motion over the range of values.  In this instance, the 
cumulative data used in computing margins for all ptients is 548,249 points.  This gives enough data for 
statistical analysis.  When the 99% predictive lineis applied to the same group of patients, the margins 
increase.  The mean is 1.62 for the (+X) direction and 1.8 for the (-X) direction.  The associated standard 
deviations are 0.3 and 0.5.  This shows an increase in predicted motion between the two approaches.   
 
It is evident from the margins that the prostate motion is small relative to current clinically acceptd treatment 
margins across most patients.  As mentioned earlier in Chapter 2, when the model estimates a margin less than 
1.5 mm, the threshold will be exceeded for clinical delivery and thus a 1.5 mm value will be assigned i  that 
instance.  From a review of the above tables, this occurs approximately 70% of the time with respect to the X-
model.  This is expected based on the mean and stanard deviation values.  Figures 3.1 and 3.2 represent th  




Figure 3.1 Polynomial fit for the X-model, CCF 101, 95% Predictive Line 
 
Figure 3.2 Polynomial fit for the X-model, CCF 115, 9 % Predictive Line 
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These figures demonstrate the pattern of motion over the first five fractions for patient CCF 101 and 115 
respectively.  The one similarity between the two figures is that there is a lack of motion in the latr l 
direction.  The resulting clinical margins are 1.5 mm in both cases.  The lack of motion in the lateral plane is 
not unexpected based on how the prostate sits in the pubic region along with the ligament structure that holds 
the prostate in place.   
 
Based on the results shown, it is reasonable to infer that a uniform model across all patients might be he best 
course in determining clinical margins for the X-model.  Approximately 70% of patients are being assigned 
margins of 1.5 mm.  There are several patients that exceed 2 mm in one direction.  However, given thate 
polynomial model consistently estimates tight margins with respect to current clinical margins, it appears that 
the 1.5 mm approach is a sufficient starting point.  Uniform margins for the X-model will be discussed further 
in future research. 
 
The next step in determining the effectiveness of this approach is to validate the model.  Validating he model 
is accomplished by taking the data from the remaining 34 fractions and comparing it with the treatment 
margins developed.  An Excel macro was developed where the predictive margins developed from the 8th order 
polynomial fit are applied to the remaining data.  The data points are either scored as falling within e 
treatment margin or falling outside the treatment margin.  The values in Table 2.1 are used to determine if the 
model performed acceptable, marginal or unsatisfactory.  In addition, current clinically accepted treatment 
margin models are shown as well for a direct comparison.  These models include the uniform 2 mm margin 
model along with the 6 mm in all directions and 4 mm posterior model.  These models were presented in detail 




Table 3.3 Summary of Comparisons between Accepted Clinical Models and the Polynomial Model for the X-
vector.  Values indicate % of data points falling outside the clinical margins. 
Patient 2 model 6/4 mm  Poly 95 Poly 99 
101 .015 0 .024 .024 
102 5.91 0 1.4 .58 
103 0 0 .16 .16 
106 2.1 0 3.3 3.3 
108 .02 0 .96 .96 
109 .05 0 1.9 1.9 
110 1.24 0 3.4 3.2 
111 .42 .04 1.3 1.30 
112 .68 0 1.8 1.8 
113 0 0 0 0 
114 .02 0 .02 .023 
115 0 0 0 0 
116 3.4 0 8.5 6.2 
117 2.8 0 7.2 7.2 
118 3.4 0 3.5 3.5 
119 2.8 0 4.9 2.8 
120 0 0 0 0 
123 2.8 0 3 2.6 
124 .23 .07 1.2 1.2 
125 .75 0 .91 .63 
126 3.7 0 3.1 2.9 
129 0 0 0 0 
130 .04 0 0 0 





The 2 mm model scored acceptable across all patients but one.  Patient CCF 102 was the only patient to fall 
outside the 5% threshold.  The majority of patients fell below the 3% value.  The 6/4 mm model had no data 
falling outside the 5% value.  The lack of data points falling outside the threshold is not the best rult.  These 
results indicate that we are irradiating too much normal tissue.  This leads to higher complication rates and a 
greater potential for secondary cancers.  The fact th t almost no data points fall outside of the margin is not a 
preferred approach.  There needs to be a balance betw en effective margins and a motion management of the 
prostate. 
 
The Polynomial model is broken down into the 95% and 99% predictive lines.  Tables 3.1 and 3.2 break down 
the corresponding margins for each approach.  In some instances the margins change significantly (> .8 mm) 
between these two models and other times the change is minimal (<.3 mm).  When the predictive margins are
applied to the group of patients, the results are quite different than the other two clinical margin approaches.  
The majority of the margins are in the 1.5-1.8 mm range.  This offers a reduction in normal tissue that will be 
irradiated during treatment.  When the 99% predictive line is applied, no patient fails in meeting eith r the 
acceptable or marginal criteria.  Margins are slight y increased as seen in Table 3.2.  This increase is expected 
based on using the 99% data point.  Determining when one model should be applied over another is not a 
definitive process and will be discussed further in the future work section.   
 
A complete review of Table 3.3 shows that the X-model for the Polynomial approach is effective in predicting 
margins for future treatment fractions.  In the case of the 95% model, only one patient is unacceptable.  No 
patients are unacceptable when using the 99% approach.  There is a reduction in treatment volume when usi g 
the Polynomial model when compared to the 6/4 mm model.  This reduction is dependent on the size of the 
predictive margins and varies by patient.  The treatm nt planning process and Dose Volume Histogram (DVH) 
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analysis will be discussed in Chapter 4.  The predictive margins are only one aspect of this analysis.  It is also 
necessary to show that the clinical impact is meaningful and will result in an effective treatment planning 
result. 
 
3.1.2 Polynomial, Y-model 
The Y-vector represents motion in the anterior / posterior directions.  This motion can be greatly influenced by 
physiological processes such as rectal gas and blader fill rate.  Unlike the X-vector where there was very little 
motion, the motion in the anterior / posterior direction is more pronounced.  Given the nature of some f these 
processes, the motion pattern will exhibit various peaks throughout the treatment process.  In order to model 
the motion effectively and obtain accurate treatment margins, the model will need to be responsive by taking 
into account even small variations in motion. 
 
The results in Table 3.1 indicate the motion is more pronounced than the X-vector.  The mean for the 95%
approach is just less than 2.5 mm and the 99% model resu ts in a mean value of 3 mm.  These values repres nt 
anterior motion.  The posterior motion for the 95% and 99% models is 2.6 mm and 3.1 mm respectively.  The
standard deviations are larger for the Y-model as compared to the X-model.  This is expected due to an verall 
increase in motion.  The 95% model has a standard deviation of 1.1 mm for both vectors.  There is an increase 
for the 99% model to 1.3 mm, which is expected due to capturing an even broader range of motion.  Figures 




Figure 3.3 Polynomial fit for the X-model, CCF 125, 9 % Predictive Line 
 
 
Figure 3.4 Polynomial fit for the Y-model, CCF 123, 95% Predictive Line 
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Figure 3.3 and 3.4 show more prostate motion than ws demonstrated with the X-model.  The spread in motion 
for patient CCF 125 is more pronounced when compared to the lateral motion.  Although each treatment 
fraction begins at the initial coordinate of (0,0,0), the motion pattern varies for each fraction.  This is in direct 
contrast to the previously presented X-model patients.  This large motion expands the prediction line a d
results in larger predictive margins.  
 
 In the case of patient CCF 125, the predictive margins for the 95% model are 3.4 mm in the anterior direction 
and 2.9 mm in the posterior direction.  Both of these margins are less than the 6/4 mm clinical model that is 
currently in use for IGRT patients.  These margins also exceed the mean over the patient population, which 
indicates this patient has more motion than the othr study patients.  When the 99% prediction line is applied 
the margins are increased to 4.1 mm and 3.7 mm respectively.  This is an increase and reduces the 
effectiveness in minimizing the volume of normal tissue being irradiated.   
 
The results for CCF 123 are similar to CCF 125.  The margins as defined by the 95% approach are 3.5 mm 
anterior and 2.7 mm posterior.  This is similar to CCF 125.  However, when the 99% criterion is applied, the 
margins for CCF 123 are 4.4 mm and 3.3 mm respectively.  This indicates that there is more motion in CCF 
123 when looking at the outlying data sets.  Both of these patients exceed the mean margins.  This is not 
indicative of all patients but underscores the need to be able to predict margins for patients on an indiv dual 
basis.  Table 3.4 shows the results of the margins as predicted using the Polynomial model in comparison with 





Table 3.4 Summary of Comparisons between Accepted Clinical Models and the Polynomial Model for the    
Y-vector.  Values indicate % of data points falling outside the clinical margins. 
Patient 2 mm 6/4 mm Poly 95 Poly 99 
101 .25 0 .033 .012 
102 5.5 .07 16.1 11 
103 2.8 .07 .09 .011 
106 7.7 .01 2 .91 
108 .61 0 .04 0 
109 8.9 .08 3.8 .77 
110 8.7 .02 5.1 2 
111 7.1 .03 2.7 1.3 
112 .82 0 .05 0 
113 .39 0 .64 .06 
114 7.4 .78 7.9 5.1 
115 16.9 .16 2.1 1 
116 12.8 .22 4.3 2.1 
117 14.4 .57 .64 .32 
118 14.7 .04 7.5 4.7 
119 4.5 .65 7.8 4.8 
120 .31 0 .15 .026 
123 14.4 .25 2.9 .84 
124 10.6 .21 18.7 18.7 
125 5.6 .3 1.6 1 
126 7.1 .02 4.7 3.4 
129 13.7 .28 17.8 6.3 
130 6.6 .18 1.9 1.6 





A review of the clinical results from Table 3.4 show measurable differences among the models.  The 2 mm 
model performed acceptably across all patients in the X-vector modeling process.  However, the Y-vector 
introduces more physiological processes that increase this motion.  For example, CCF 123 had 14.4% of the 
data points falling outside of the margin.  A total of 7 patients performed unacceptably using the defined 
criteria for the 2 mm model.   
 
The 6/4 mm model performs adequately.  This is consistent with the concept that larger margins are effctive 
in prostate therapy.  All patients fell outside of the margins less than 1% of the time.  This small value further 
supports the theory that uniform margins that are too large lead to an increase in dose to normal tissue while 
providing no additional benefit in dose to the prostate. 
 
The Polynomial model results show significant differences from either of the two clinical models.  The 2mm 
model performed unacceptably in over 29% of patients while the 6/4 mm model results show margins that are 
too large.  Reviewing the 95% predictive model first shows a total of four patients falling into the unacceptable 
criteria. For example, CCF 124 had 18.4% of the data points fall outside of the clinical margins.  This most 
likely indicates that the data accumulated over the first five fractions is not representative of the rest of the 
treatment fractions.  The model predicted clinical m rgins of 1.5 mm in either direction.  This value is the 
threshold set by the model below which treatment delivery cannot be delivered accurately.   
 
The 99% approach shows an improvement.  A total of three patients performed unacceptably based on the 
same criteria.  CCF 129 had a reduction from 17.8% of the data points falling out of the margins to 6.3%when 
comparing 95% and 99% predictive line models.  There are certain instances when moving from the 95% 
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model to the more encompassing 99% model is justified.  Determining when this is necessary is not definitive 
and should be left to the clinician based on the indiv dual patient.  Overall the Polynomial model forthe Y-
vector performs satisfactory based on the results shown above.  Using the 99% predictive line results in 85% 
of the patients scoring either adequate or marginal.   
 
3.2.3 Polynomial, Z-model 
The Z-vector represents motion in the superior / infer or directions.  As is the case of the Y-vector, motion can 
be greatly influenced by physiological processes such as rectal gas and bladder fill rate.  Given the nature of 
some of these processes, the motion pattern will exhibit various peaks throughout the treatment process.  There 
is a possibility that motion found in the Z-vector will correlate with motion in the Y-vector.  This correlation 
will be reviewed later in this chapter but should be noted.  If these two models are related, there is a possibility 
of developing a model to predict motion in both models while looking at a combined set of data. 
 
The results in Table 3.1 indicate the motion is very similar to the Y-vector.  The mean for the 95% predictive 
approach is just less than 2.6 mm and the 99% model resu ts in a mean value of less than 3 mm.  These values 
represent motion in the superior direction.  The inf r or motion for the 95% and 99% models is 2.8 mm and 3.5 
mm respectively.  These mean values are almost identical with the Y data.  This further confirms the potential 
for correlation between these components. The corresponding standard deviations are larger based on the 
overall increase in motion. The 95% model has standard eviations of 1 and 0.87.  There is an increase for the 
99% model, which is expected due to capturing an eve  broader range of motion.  These values are 1.2 and .98 
respectively.    The standard deviations are slightly less for the Z-model, which can be attributed to the data 





Figure 3.5 Polynomial fit for the Y-model, CCF 119, 95% Predictive Line 
 
 
Figure 3.6 Polynomial fit for the Y-model, CCF 129, 95% Predictive Line 
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The figures above represent the polynomial model for the Z-vector.  The 95% predictive lines are shown in 
these figures.  CCF 119 shows significant motion variation over the first five fractions.  This is accounted for 
in the model, which is evidenced by the motion of the predictive lines.  There is a large motion deviation in the 
first 100 seconds for one fraction.  This is more than likely attributed to rectal gas.  This deviation s not seen 
in the other fractions that make up the clinical margins.  The model needs to account for this since the largest 
point of inflection is used to determine the margin. 
 
Patient CCF 129 is shows a pattern of motion that is limited.  The margins are small relative to current clinical 
margins and may or may not be representative of the overall motion pattern for this patient.  Table 3.5












Table 3.5 Summary of Comparisons between Accepted Clinical Models and the Polynomial Model for the Z-
vector.  Values indicate % of data points falling outside the clinical margins. 
Patient 2 mm 6/4 mm Poly 95 Poly 99 
101 .24 .21 .21 .21 
102 9 .02 7 2.3 
103 4.3 .02 1.22 .97 
106 15.1 .05 2.9 1.1 
108 1.1 0 .84 0 
109 6.1 .45 1.01 .76 
110 13.3 2.4 7.3 4.4 
111 6.6 .25 8.4 5.7 
112 5.2 0 1.9 .074 
113 .83 .01 .32 .32 
114 9.6 .57 10.3 6.3 
115 17.9 .03 2.8 .73 
116 16.9 .12 1.5 .34 
117 14.1 .69 1.92 1.1 
118 8.6 0 2.3 .55 
119 21.2 .09 4.6 3.4 
120 .31 0 .21 0 
123 7.2 .01 3.4 3.3 
124 6 0 5.5 5.2 
125 10.4 .55 3.7 2.8 
126 8.2 .03 6.2 5 
129 5.7 .02 3.4 3.2 
130 2.4 .54 1.6 1.4 





The results shown above reflect the motion associated with the Z-vector.  The 2 mm model does not perform 
satisfactory.  A total of 8 patients had unacceptable results based on the criteria.  This demonstrates that a 
uniform margin of 2 mm is not appropriate for clinical treatments.  When reviewing the results of the 6/4 mm 
model, the results are as expected.  The prostate mov s outside of the treatment volume a small percentag  of 
the time (< 1%).  This confirms that the margins are too large across the patient population.  All patients scored 
adequately with this approach. 
 
The Polynomial model with the 95% prediction line performs satisfactory based on the results above.  Only 
two patients perform unacceptably based on the critria and one of the patients, CCF 114 misses passing by 
0.3%.  There are a larger number of patients falling within the marginal category.  One of the figures above 
represented patient CCF 119.  This patient scored in the adequate range.  The second patient CCF 129 also 
performed in the acceptable criteria.  This is important because the margins were relatively small (1.9 mm, 2.5 
mm).  Overall, the 95% prediction line model performed well over the 24 patients. 
 
The Polynomial model utilizing the 99% prediction li e also scored well.  All patients show a decrease in the 
amount of data points falling outside the margins as expected.  Only one patient had unacceptable results with 
this approach.  CCF 131 did not perform well for the Y-model either.  This appears to be a case of a bad 
sampling of data during the first five fractions.  Both CCF 119 and CCF 129 saw decreases but not significant.  
Additional work will be needed in order to determine when an increase in margin is warranted based on the 
reduction in points outside of the field.  With 23 of the 24 patients performing either acceptable or ma ginal, 




3.1.4 Summary of Polynomial Model Results 
A total of 24 patients have been modeled using the Polynomial approach.  The model was further broken down 
into two separate methods.  One model used a 95% predictive line to determine clinical margins while the 
second approach used a 99% predictive line.  Both appro ches were attempted in order to determine which 
model would provide better margins.   
 
The X-model has been consistent across all of the pati nts presented and that consistency is present in most all 
of the patients presented.  In addition, there is very little difference whether the clinician chooses the 95% or 
the 99% prediction line for margins.  However, it should be noted that due to the overall lack of motion in the 
X-vector, the model threshold was utilized in over 70% of the patients.  In this research, a total of 14 of the 24 
patients (95% Polynomial) were assigned the 1.5 mm margins.  The other 10 patients showed minimal 
increases in margins.  These results indicate that margins are predictable and a uniform approach across the 
entire population can be assumed for the X-model.   
 
Unlike the X-model, the Y-model experienced more motion over the course of 24 patients.  This is not 
unexpected in that the bladder fill along with rectal gas would have a significant influence on the pattern of 
motion.  The Polynomial model performed well under these conditions.  A total of 16 patients in the 95% 
model and 19 patients in the 99% model performed acceptably.  This is lower than the X-model but not 
unexpected given the factors that affect motion in the anterior / posterior directions.  The main concer  with 
the results is the subset of patients that performed unacceptably with greater than 10% falling outside the 
range.  This was reduced with the 99% model.  Even with several patients outside of the 10% range, 87.5% of 
the patients scored acceptable or marginal.  The 8th order Polynomial fit is successful in predicting prostate 
motion for the Y-model in most of the patients. .   
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The results of the Z-model are similar to the results presented regarding the Y-model.  Although no correlation 
between the two movements has been shown, there appears to be a qualitative relationship between the vectors 
on several patients.  The results for the Z-model are consistent with the Y-model in the number of patients who 
perform acceptably under the criteria.  The Z-model actually performs better from the standpoint of having less 
patients fall into the unacceptable category.  An increase occurs in the marginal range in both the 95% and the 
99% models.  The Z-model performs well across all patients.  Over 90% of the patients scored in the 
acceptable or marginal range with either model.   
 
Overall, the Polynomial model is effective in predicting clinical treatment margins and reducing the ov rall 
volume of normal tissue that will be irradiated.  There are several patients where the model does not accurately 
model motion.  In these cases, it will be necessary to look at ways in order to minimize this from happening in 
future cases.  In addition, due to a lack of motion in the lateral direction, a uniform model across all p tients 
appears to be satisfactory for the general patient population. 
 
3.2 Cumulative Frequency Distribution Model (CFD) 
In order to determine the effectiveness of the Polyn mial model, a different statistical approach was 
researched.  The CFD was determined to be an acceptbl  approach at modeling the prostate motion.  One
advantage to this model is that it is very simple to apply.  A ranking of the data allows the user to determine 
the 95% and 99% points in the set.  Another benefit is that this is using the actual patient data so the effects of 
a model are not present.  This has the potential to reduce the influence of distributions that are not accurate or 




Table 3.6 Clinical margins (in millimeters) for the CFD model utilizing the 95% data point. 
Patient +X -X +Y -Y +Z -Z 
101 1.5 1.5 1.8 1.5 2.6 1.5 
102 1.5 2.8 1.5 1.5 1.5 2.2 
103 1.5 1.5 3.3 1.8 2.3 1.7 
106 1.5 1.5 1.5 2.4 1.5 2.5 
108 1.5 1.5 3.8 1.9 2.9 1.5 
109 1.5 1.5 1.7 1.5 2.8 1.7 
110 1.5 1.5 2.6 1.5 1.7 1.5 
111 1.5 1.5 1.5 2.3 1.5 1.5 
112 1.5 1.5 2.3 1.5 3 1.5 
113 1.5 1.5 1.5 1.5 1.5 1.5 
114 1.5 1.5 2.5 1.5 2.1 1.5 
115 1.5 1.5 1.5 2.3 1.5 2.9 
116 1.5 1.5 1.5 1.5 2.1 1.5 
117 1.5 1.5 6.8 2.7 4 2.1 
118 1.5 1.5 1.5 2.2 1.5 2.6 
119 1.5 1.5 1.5 1.5 1.5 2.4 
120 1.5 1.5 1.7 1.5 1.9 1.6 
123 1.6 1.5 2 1.8 1.5 2.1 
124 1.5 1.5 1.5 1.5 1.5 1.5 
125 1.5 1.5 2.9 1.5 2.8 1.5 
126 1.5 1.5 1.5 1.9 1.5 1.8 
129 1.5 1.5 1.5 1.5 1.5 1.5 
130 1.5 1.5 1.5 1.5 1.5 1.5 
131 1.5 1.5 1.6 1.5 1.5 1.5 
Mean 
1.50 1.55 2.12 1.74 1.99 1.79 
S Dev. 




Table 3.7 Clinical margins (in millimeters) for the CFD model utilizing the 99% data point. 
Patient +X -X +Y -Y +Z -Z 
101 1.5 1.5 2.7 2.6 4.2 2.8 
102 1.5 2.8 1.5 1.5 1.5 2.4 
103 1.5 2 4.7 3.2 3.3 3.6 
106 1.5 1.5 1.5 3.6 1.2 2.9 
108 1.5 2 4.2 1.8 3.3 1.5 
109 1.5 1.5 4.9 1.9 6.2 2.5 
110 1.6 1.5 3 1.5 4.5 1.9 
111 1.5 1.5 1.5 3.1 1.5 1.8 
112 1.5 1.5 3 1.5 5.5 2.4 
113 1.5 1.5 1.5 1.5 1.5 1.5 
114 1.5 1.5 3.2 1.5 3.6 1.5 
115 1.5 1.5 1.5 3.4 1.5 3.6 
116 1.6 1.5 2.9 1.5 4.9 2 
117 1.5 1.5 8.5 5.1 6.8 3.9 
118 1.5 1.5 1.5 2.9 1.5 2.9 
119 1.5 1.6 1.5 1.7 4.8 3.2 
120 1.5 1.5 3.4 1.5 5.6 2.7 
123 1.9 1.5 2.4 2.2 1.5 2.4 
124 1.5 1.5 1.5 1.5 1.5 1.7 
125 1.5 1.5 3.7 1.6 3.7 1.5 
126 1.5 1.5 2.2 1.5 2.2 1.5 
129 1.5 1.5 1.5 3.6 1.5 2 
130 1.5 1.5 1.5 2.1 2.1 5.2 
131 1.5 1.5 1.6 2.1 1.8 2 
Mean 
1.52 1.6 2.72 2.27 3.15 2.47 
S Dev. 




The CFD approach is simplified statistical method that does not require complex equations or functions in 
order to generate predictive margins.  In order to determine its effectiveness when compared to other clinical 
models, the results will be divided into sections that discuss each vector component separately.  In addition, 
this will be effective in comparing results that were obtained with the Polynomial approach. 
 
3.2.1 CFD, X-model   
The results for the X-model using the CFD approach are summarized in the Tables 3.6 and 3.7 above.  
Analysis of the 95% data point model show that the lat ral margins are smaller than what was seen the 
Polynomial approach.  The means are 1.5 and 1.6 respectively.  This is not a significant difference but it does 
show that the majority of the margins were assigned th  threshold value of 1.5 mm in either direction.  The 
standard deviation is .02 and .26 mm.  This confirms that there is a lack of variation from the mean which 
suggests minimal data motion over the patient population.  This is consistent with the Polynomial model. 
 
The results of the 99% data point analysis are verysimilar.  The means are reported as 1.5 and 1.6 respectively.  
The motion detected in the negative lateral direction has only a slight difference in the mean between th  95% 
and 99% models.  If there is not a significant increase in margins between approaches it confirms that the data 
is limited in motion.  When the prostate demonstrates limited displacement, a uniform approach is supported.  
The benefit to a uniform model is that margins can be generalized over a patient population.  This is the case in 
the clinical models that are analyzed when comparing the predictive margin approaches (2 mm and 6/4 mm).  
The issue is that the margins being suggested are small and based on the minimum size necessary in order to 
deliver an accurate treatment.  Another size margin might be more appropriate for the general population.  That 





Figure 3.7 CFD for Patient CCF 101, X-model 
 
 
Figure 3.8 CFD for Patient CCF 115, X-model 
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The first figure represents patient CCF 101.  As previously shown in the Polynomial model, there is mini al 
motion (< 2 mm) in the lateral directions.  The margins summarized in Tables 3.6 and 3.7 demonstrate th  the 
CFD supports that result.  Figure 3.7 displays a uniform displacement around the zero point over the first ive 
fractions.  This results in very small margins in comparison to current clinical models.  The predicted margins 
are 1.5 mm which is the threhold for treatment delivery established in this research.  The CFD approach is 
consistent with the Polynomial model.  When there is limited motion, the model will predict tight margins with 
either approach. 
 
Patient CCF 115 has less motion than the previous patient.  This again is supported by the Polynomial 
approach.  The motion pattern does not exceed 1 mm across all five fractions.  The 1.5 mm threshold will be 
used in setting the margins for this particular patient.  The 1.5 mm margin is consistent throughout the CFD 
approach.  The mean is close to 1.5 in either direction and model.  The Polynomial approach has a mean of 1.6 
and 1.8 across the 99% model.  The results indicate th  the CFD approach predicts narrow margins across the 
patient population for the X-model in comparison to the Polynomial model.  This would make the model more 
effective if it results in a reduction of data points falling outside of the margins when compared to other 
clinical models.   
 
Given the overall lack of motion in the lateral direction of the prostate, the model assumes the threshold 
margins in over 95% of the patients.  This is higher t an in the Polynomial model.  The  comparison of the 





Table 3.8 Summary of Comparisons between Accepted Clinical Models and the CFD Model for the X-vector.  
Values indicate % of data points falling outside thclinical margins. 
Patient 2 model 6/4 mm CFD 95 CFD 99 
101 .015 0 .024 .024 
102 5.91 0 1.8 1.8 
103 0 0 .16 .16 
106 2.1 0 3.3 3.3 
108 .02 0 .96 .022 
109 .05 0 1.9 1.9 
110 1.24 0 3.4 3.4 
111 .42 .04 1.3 1.3 
112 .68 0 1.8 1.8 
113 0 0 0 0 
114 .02 0 .023 .023 
115 0 0 0 0 
116 3.4 0 11.7 10.8 
117 2.8 0 7.2 7.2 
118 3.4 0 3.5 3.5 
119 2.8 0 9.7 7.9 
120 0 0 0 0 
123 2.8 0 4.2 2.2 
124 .23 .07 1.2 1.2 
125 .75 0 2.6 2.6 
126 3.7 0 3.1 3.1 
129 0 0 0 0 
130 .04 0 2.4 2.4 





The results shown in Table 3.8 summarize the performance of predictive margins as determined using the CFD 
approach.  The results show that the model performs adequately for 21 of the 24 patients when using the 95% 
criteria.  Only one patient had an inadequate result based on the established criteria.  When compared with the 
other clinical models, the 95% model is equivalent  in delivering dose within acceptable treatment margins.  
The 2 mm model has similar results.  The 6/4 mm model results demonstrate that there is little gain in accuracy 
for the increase in margins and dose to normal tissue. 
 
When reviewing the 99% model, there is very little change in margins or results.  There is a minimal reduction 
in the number of data points falling outside of the margins.  This is confirmed by reviewing the mean margins.  
Due to the minimal motion in the prostate in the lat r l directions, there is no gain in applying the 99% model 
for patients.  Patient CCF 116 was inadequate with a value of 11.7% in the 95% approach and improved only 
slightly to 10.8% when using the 99% criteria.   
 
The results with the CFD model are similar to the Polynomial model for the X-vector.  Over 90% of the 
patients perform adequately under the set criteria.  The limited motion of the prostate as demonstrated by both 
models is consistent with a uniform margin approach. 
 
3.2.2 CFD, Y-model   
The Y-vector has more motion due to physiological proccesses than the X-vector.  The reasons for this have
been previously discussed.  The Polynomial approach  for the Y-vector resulted in over 90% of the patien s 




Figure 3.9 CFD for Patient CCF 115, Y-model 
 
Figure 3.10 CFD for Patient CCF 125, Y-model 
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A review patient CCF 115 shows more motion in the Y-vector.  This motion is anticipated based on the results 
shown earlier.  The CFD approach is effective in showing where the majority of the motion occurs.  In the case 
of CCF 115, the motion is skewed in the posterior drections over all five fractions.  This leads to larger 
margins for the posterior edge of the prostate gland. The corresponding margins for the 95% approach are 1.5 
mm in anterior direction and 2.3 mm in the posterior.  The model does note the posterior motion of the gland.  
The CFD model is able to predict margins outside of the model threshold for this patient.  The Polynomial 
model was more effective in modeling this movement and extending the posterior margin.  When reviewing 
the 99% approach, the same issue can be noted with regards to posterior motion.  The model predicted a 3.4 
mm margin.  This increase is an improvement but still below the 3.8 mm predicted with the Polynomial model.   
 
Patient CCF 110 presents with the opposite motion pattern.  Prostate displacement occurs in the anterior 
direction over the first five fractions.  The CFD approach models this motion by extending margins in the 
anterior direction to 2.6 mm in the 95% and 3 mm in the 99% models.  There are more data points at extended 
distances from the isocenter which the model is able to incorporate in its prediction.  These margins are still 
significantly smaller than the Polynomial model.  The Polynomial approach predicts 3 mm at the 95% and 3.5 
mm at the 99% data point.   
 
The CFD model predicts smaller margins when compared to the Polynomial model across the patient 
population in this research.  This is effective if it results in the same outcome as seen the Polynomial model.  





Table 3.9 Summary of Comparisons between Accepted Clinical Models and the CFD Model for the Y-vector.  
Values indicate % of data points falling outside thclinical margins. 
Patient 2 mm 6/4 mm CFD 95 CFD 99 
101 .25 0 1.9 .037 
102 5.5 .07 16.1 16.1 
103 2.8 .07 1.8 .097 
106 7.7 .01 7.2 4.1 
108 .61 0 .08 0 
109 8.9 .08 14.2 4 
110 8.7 .02 7.4 6 
111 7.1 .03 5.6 3.7 
112 .82 0 .42 .21 
113 .39 0 .64 .64 
114 7.4 .78 10.5 9.8 
115 16.9 .16 11.5 2.4 
116 12.8 .22 22.1 18.5 
117 14.4 .57 .74 .28 
118 14.7 .04 12.2 5.8 
119 4.5 .65 11.7 9.1 
120 .31 0 1.1 .075 
123 14.4 .25 19.3 8.6 
124 10.6 .21 18.7 18.7 
125 5.6 .3 7.4 5.7 
126 7.1 .02 9.9 9.6 
129 13.7 .28 28.4 12.5 
130 6.6 .18 12.8 12.5 





The summary of the results in Table 3.9 show a model that does not perform well in predicting treatment 
margins.  A total of 50% of the patients had inadequate results when using the 95% criteria.  This is up 
substantially from the Polynomial model.  The number of data points falling outside the margins is reduced to 
29% when using the 99% criteria.  These results demonstrate that the CFD does not perform adequately across 
the population.   
 
The 2 mm model underperforms as well.  A total of 29% of the patients had an inadequate result using th s 
approach.  A uniform 2 mm margin approach does not appear to be an acceptable approach in applying 
margins to prostate motion for the Y-vector.  As exp cted, the 6/4 mm model showed the effect of over 
margining.  None of the patients exceeded the margins more than 1% of the time.  
 
The CFD approach is not recommended for predictive margins when reviewing the results of the Y-model.  
The model consistently underestimates the necessary m rgins for accurate motion management.  This is even 
more pronounced when compared to the Polynomial model.  The CFD model will be analyzed when applied to 
the Z-vector data in the next section. 
 
3.2.3 CFD, Z-model   
The Z-vector has a similar motion pattern to the Y-vector.  The Polynomial approach resulted in over 95% of 
the patients scoring an adequate or marginal result when using the 99% criteria for the Z-model.  Figures 3.11 





Figure 3.11 CFD for Patient CCF 125, Z-model 
 
Figure 3.12 CFD for Patient CCF 111, Z-model 
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The review of the Z-model for the CCF 125 shows the majority of motion is in the superior direction.  There is 
minimal motion (< 2 mm) in the inferior direction.  The lack of motion in the inferior direction will result in a 
margin of 1.5 mm being assigned in both the 95% and 99% approaches.  This is in contrast to the Polynomial 
model where the inferior margins were estimated in the range of 2.4 for the 95% and 2.6 mm for the 99% 
given the same dataset.  The 95% approach predicts a margin of 2.8 mm in the superior direction while th
Polynomial model predicts 3.1 mm.  The estimates from both approaches are different, especially along the 
superior border. 
 
Patient CCF 111 shows a more uniform motion pattern with minimal motion (< 2mm) along the superior 
border.  This is in direct contrast to patient CCF 125.  The result of this motion pattern is that the pr dicted 
margins for the 95% model are 1.5 mm in either direction.  The Polynomial model estimated margins to be 1.5 
and 1.9 mm.  With minimal displacement, either approach estimates small margins.  The 99% criteria 
estimates margins of 1.5 mm superiorly and 1.9 mm inferiorly.  This is minimal gain in the inferior direction 
but consistent with the Polynomial model.   
 
The results of the two patients above show that the CFD model in these instances predicts small margins w th 
respect to current clinical models.  The model thres old is assigned in 54% of the patients.  Given th results 
previously presented with the Polynomial model, it is not probable that these predictive margins will satisfy 
the acceptance criteria set forth for this research.  Table 3.10 gives the results for the CFD model when applied 





Table 3.10 Summary of Comparisons between Accepted Clinical Models and the CFD Model for the Z-vector.  
Values indicate % of data points falling outside thclinical margins. 
Patient 2 mm 6/4 mm CFD 95 CFD 99 
101 .24 .21 .21 .21 
102 9 .02 6.9 4.8 
103 4.3 .02 6.4 .56 
106 15.1 .05 9.3 6.3 
108 1.1 0 1.9 1.7 
109 6.1 .45 6.6 1.8 
110 13.3 2.4 21.2 5.5 
111 6.6 .25 15.6 5.1 
112 5.2 0 5.6 2.8 
113 .83 .01 3.2 3.2 
114 9.6 .57 15.3 14.2 
115 17.9 .03 4.4 2.6 
116 16.9 .12 29.2 12.1 
117 14.1 .69 8.4 1.4 
118 8.6 0 4.4 3 
119 21.2 .09 33.8 1.8 
120 .31 0 .61 0 
123 7.2 .01 7.3 4.2 
124 6 0 7.3 6.8 
125 10.4 .55 5.2 3.5 
126 8.2 .03 8 6.5 
129 5.7 .02 14.4 13.3 
130 2.4 .54 8.3 1.6 





A review of results in Table 3.10, demonstrates that t e CFD model using the 95% criteria is not suitable in 
modeling the Z-vector.  A total of 29% of the patien s performed inadequately using the established criteria.  
The patients in this category had larger misses when compared to the Polynomial model.  For example, CCF 
131 had 34.6 percent of the data points fall outside of the margins.  CCF 119 had a total of 33.8% as well.  
Misses of this size indicate that the model is not suitable for predictive margins.  Another issue is the increase 
in the number of patients scoring marginally.  A total of 45.8% of the patients had marginal results.  This is in 
contrast to the Polynomial model which had 20.8% of the patients score marginally.  The performance of the 
CFD model using the 95% criteria is well below the Polynomial. 
 
There is improvement in the model when using the 99% criteria.  A total of 16.7% of the patients have 
inadequate results when using the same criteria.  The most significant improvement is seen in CCF 119.  The 
95% model has 33.8% falling outside the margins while t e 99% has only 1.8%.  This reduction indicates that 
the majority of the motion was just outside of the margins determined in the 95% approach.  These results are 
still less than those obtained with the Polynomial odel.  The increase in margins when comparing the CFD
95% versus CFD 99% is not significant.  This is most likely related to the use of the actual data as opposed to a 
modeling approach such as the Polynomial.   
 
The CFD for the Z-model does not perform as well as the Polynomial model.  It consistently under predicts 
margins and leads to large amounts of data points falling outside of the treatment margins.  A summary of the 





3.2.4 Summary of CFD Model Results 
The CFD is a simplified statistical approach that ws attempted in order to determine the best method to model 
prostate motion.  A Polynomial model has been developed that performed satisfactory across 24 patients.  The 
CFD model has been applied to those same patients.  The reasoning behind the CFD approach is that it utilizes 
actual data points for modeling and it is a statistical method that can be easily implemented.  The crit ria for 
determining the success of a model is given in Table 2.1.  Once the data is ranked, the 95% and 99% data 
points are determined and used as the clinical margins.  These are then compared with other clinical models to 
determine effectiveness of the model.   
 
Results of the CFD approach with respect to the X-model are very similar to the Polynomial model.  The X-
model scored well using the CFD approach.  The main reason behind this is that there is very little motion in 
the lateral directions of the prostate and that the model threshold of 1.5 mm is assigned in a number of the 
patients.  This is important since margins that are too small cannot be delivered due to uncertainties such as 
setup error and patient positioning.  The performance of the CFD for the X-model is summarized in Table 3.8. 
 
The Y-model has more motion when compared to the X-v ctor as seen in the results of the Polynomial 
approach.  The results for the Y-model using the CFD are given in Table 3.9.  The results for the Y-model 
across the population are poor.  Approximately 54% of the patients were inadequate using the 95% criteria.  
This is up from 20.8% using the Polynomial approach.  With only six patients scoring in the adequate rnge 
and 5 in the marginal range, the 95% model is not suitable for clinical delivery.  The 99% approach is 
improved with approximately 29% of the patients not meeting the criteria for either adequate or marginal 
performance.  These results are significantly higher t an the Polynomial model and represent an 
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underperforming model.  The Y-model is ineffective at predicting motion regardless of which approach (i.e.
95% or 99%) is chosen.   
The results for the Z-model are mixed.  There is improvement from the Y-model across all criteria.  However, 
the adequate criterion is only met by 25% of the patients using the 95% approach.  This is not clinically 
acceptable.  There is slight improvement in the 99% model ( 58% are adequate) but not enough to consider this 
as an alternative to the Polynomial model.  A total f 7 and 5 patients respectively had inadequate results in the 
95% and 99% approaches.  This is above the Polynomial model.  The CFD model does not model motion that 
results in large displacements of the prostate.   
 
3.3 The Bayesian Model 
The initial approach to modeling prostate motion cetered on the Polynomial model.  This model was found to 
be suitable across a population of 24 patients.  In order to validate this approach, a more straightforward 
statistical method was attempted.  The CFD model was then applied to the same 24 patients.  The results were 
mixed and overall, the model underperformed across a majority of the patients.  The third and final method 
attempted is the Bayesian model.  The theory behind t is statistical model has been presented in Chapter 2.   
 
One advantage of the Bayesian method is that it uses the likelihood as a function to predict motion.  The 
likelihood function is determined by using a model that accurately fits the data.  In this case, a Gaussi n model 
was chosen based on research (Khan, 2008).  The predictiv  margins as determined by the Bayesian approach 




Table 3.11 Clinical margins (in millimeters) for the Bayesian model utilizing the 95% data point. 
Patient +X -X +Y -Y +Z -Z 
101 1.5 1.5 1.7 1.6 2.1 1.7 
102 1.5 2.7 1.5 1.5 1.6 2.3 
103 1.6 1.5 3.8 3 2.7 2.9 
106 2 2.1 1.7 3 2.1 3.4 
108 1.9 2.1 3.8 2.9 3.5 2.1 
109 1.5 1.5 2.9 2.3 3.6 3.5 
110 1.5 1.5 3 1.5 2.6 2.1 
111 1.5 1.5 1.5 3 1.5 1.8 
112 1.5 1.5 2.5 2.3 4.2 3 
113 1.5 1.5 2.4 2 2.4 2 
114 1.5 1.5 2.3 2 2.4 2 
115 1.5 1.5 2.3 2 2.4 2 
116 1.5 1.5 2.1 2.3 3.3 3.8 
117 1.5 1.5 5.4 5.7 3.8 4.2 
118 1.5 1.5 1.5 2.6 1.5 3 
119 1.5 1.5 1.5 2.6 1.5 3.1 
120 1.5 1.5 2.4 1.8 2.9 3.2 
123 2.2 2.2 2.7 2.9 1.5 2.6 
124 1.5 1.5 1.5 1.5 1.5 2.1 
125 1.5 1.5 3.3 2.7 3.1 1.9 
126 1.5 1.5 1.5 2.3 1.5 2 
129 1.5 1.5 2 2.6 1.5 2.2 
130 1.5 1.5 2.2 2.5 1.5 2.2 
131 1.5 1.5 1.9 1.5 2.4 1.8 
Mean 
1.57 1.63 2.39 2.42 2.37 2.54 
St. Dev 




Table 3.12 Clinical margins (in millimeters) for the Bayesian model utilizing the 99% data point. 
Patient +X -X +Y -Y +Z -Z 
101 1.5 1.5 2.1 2.1 2.4 2.1 
102 1.5 3.7 1.5 1.9 2 2.8 
103 2 1.6 4.6 3.8 3.4 3.6 
106 2.5 2.6 2.2 3.6 2.7 4 
108 2.3 2.6 4.5 3.7 4.2 2.8 
109 1.5 1.5 3.5 2.9 4.5 4.3 
110 1.6 1.8 3.5 1.8 3.2 2.7 
111 1.5 1.5 2 3.5 1.6 2.1 
112 1.5 1.5 3 2.8 5 3.8 
113 1.8 1.5 2.8 2.5 2.9 2.5 
114 1.5 1.5 2.8 2.5 2.9 2.5 
115 1.5 1.5 2.8 2.5 2.9 2.5 
116 1.8 1.5 2.6 2.8 4.2 4.6 
117 1.5 1.5 6.8 6.9 4.8 5.2 
118 1.5 1.5 1.5 3 1.9 3.5 
119 1.5 1.5 1.5 3 1.8 3.6 
120 1.5 1.5 2.9 2.3 3.6 4 
123 2.7 2.7 3.3 3.6 1.5 3 
124 1.5 1.5 1.5 1.5 1.5 2.4 
125 1.5 1.5 4 3.4 3.7 2.4 
126 1.5 1.9 1.5 2.7 1.7 2.4 
129 1.5 1.5 2.6 3.1 1.7 2.6 
130 1.5 1.5 2.8 3.1 1.7 2.6 
131 1.5 1.7 2.3 1.7 2.9 2.3 
Mean 
1.67 1.77 2.86 2.94 2.86 3.09 
St. Dev 




A total of 24 patients have been analyzed using three different statistical methods.  The first two approaches 
centered on the Polynomial model and the Cumulative Frequency Distribution.  The Bayesian model is the 
final approach attempted.  Using a function that fits the data, a model is developed using the 95% and 99% 
data points.  Each vector model is presented in detail in the following sections. 
 
3.3.1 Bayesian, X-model 
The results for the X-model using the Bayesian approach are summarized in the Tables 3.8 and 3.9 above.  
Analysis of the 95% data point model shows that the lateral margins are larger than was seen with the CFD
approach but almost identical with the Polynomial model.  The mean is 1.6 mm and 1.6 mm respectively.  The
lack of difference between all three models is indicative that the lateral motion of the prostate is be t modeled 
using a uniform margin approach.  The standard deviation is .03 and .1 mm with the Bayesian model.  This 
confirms that there is a lack of variation from across the population. 
 
The results of the 99% data point analysis are similar.  The mean is reported as 1.7 mm and 1.8 mm 
respectively.  There is an increase in margins in both lateral directions but not by a significant amount.  If there 
is not a significant increase in margins between approaches it confirms that the data has limited motion.  The 
results with the Bayesian approach are similar to the previous results presented for both models.  The standard 
deviation for the 99% data point approach is .35 and .31.  This increase is not unexpected based on the model 






Figure 3.13 Posterior Distribution for Patient CCF 101, X-model 
 




The Bayesian model for CCF 101 demonstrates limited motion over the first five fractions.  The distribution is 
nearly centered in along the zero point.  This shows a uniform motion pattern. The predictive margins fall 
below the threshold of 1.5 mm as set in this research.  This result is seen in the other models as well.  There is 
no change in margin whether the 95% or the 99% points are used.   
 
The second patient shown is CCF 131. The posterior distribution shows a skew to the postive lateral margin 
during the first five fractions.  This is similar with CCF 101 in that the predictive margins will be 1.5 mm as 
well.  The margins do not change whether choosing the 95% or 99% points.   
 
The posterior distribution shows similar results with the Polynomial and CFD models.  The mean and standard 
deviation across all three models are not signficnatly different.  The results of the Bayesian model ar  
consistent with previous modeling methods.  The results of the Bayesian model applied across all patients is 










Table 3.13 Summary of Comparisons between Accepted Clinical Models and the Bayesian Model for the X-
vector.  Values indicate % of data points falling outside the clinical margins. 
Patient 2 mm 6/4 mm Bayes 95 Bayes 99 
101 .015 0 .024 .02 
102 5.91 0 2.1 .54 
103 0 0 .16 .01 
106 2.1 0 2.1 2.1 
108 .02 0 .01 .01 
109 .05 0 1.9 1.9 
110 1.24 0 3.4 3.2 
111 .42 .04 1.3 1.3 
112 .68 0 1.8 1.8 
113 0 0 0 0 
114 .02 0 .02 .02 
115 0 0 0 0 
116 3.4 0 11.7 8.5 
117 2.8 0 7.2 7.2 
118 3.4 0 3.5 3.5 
119 2.8 0 9.7 9.7 
120 0 0 0 0 
123 2.8 0 2.7 2.1 
124 .23 .07 1.2 1.2 
125 .75 0 2.6 2.6 
126 3.7 0 3.1 2.9 
129 0 0 0 0 
130 .04 0 2.4 2.4 






The results of the clinical comparisons show strong similarities with the Polynomial and CFD approaches.  
There is very little difference between the 95% and99% models.  The consistency demonstrates a uniform 
margin approach will be effective in managing prostate motion for patients. 
 
A review of the 95% data shows that only one patient was unacceptable.  CCF 116 had 11.7% of the data fall 
outside of the treatment margins.  That is the same for the CFD model but higher than the 8.5% measured with 
the Polynomial method.  However, when the 99% criterion is applied, CCF 116 falls into the marginal 
category with only 8.5% falling outside of the margins.   
 
A review of the 99% model shows that no patients are unacceptable with respect to the established criteria.  
The Bayesian model outperforms the CFD.  In comparison to the Polynomial model, there is very little 
difference.  Several patients have a slightly higher rate of data points falling outside the margins but the 
Bayesian approach has slightly smaller margins averaged over 24 patients versus the Polynomial model wh n 
using the 95% data. 
 
3.3.2 Bayesian, Y-model 
The Y-model shows significantly more motion (> 2 mm) than seen in the X-model.  The Polynomial model 
had over 90% of the patients score as acceptable, while the CFD approach had only 50% rate as score in the 
acceptable range with the 95% model.  Since the majority of patients motion is Gaussian in nature (Khan, 
2008), the Bayesian model should be effective in estimating motion.  Figures 3.15 and 3.16 represent the 




Figure 3.15 Posterior Distribution for Patient CCF 113, Y-model 
 




A review of both plots shows the Y-vector exhibits more motion than seen in the X-vector.  The width of the 
posterior distribution is increased in both patients as comapared to the X-vector models.   As previously 
mentioned, the increase in motion is primarily contributed to rectal gas, bladder fill rate and respirato y 
motion.   
 
CCF 113 shows a relatively symmetric pattern of motion around the zero point.  The margins as predicte 
using the 95% criteria are 2.4 and 2 mm respectively.  When applying the 99% criteria the margins are 
increased to 2.8 and 2.5 mm.  The mean for the Y-model using the 95% value are 2.36 mm and 2.46 mm.  The
mean increases to 2.81mm and 2.99 mm when applying the 99% value.  CCF 113 is consistent with the mean 
of the patient population. 
 
CCF 115 shows a similar pattern of motion over the first five fractions.  This is reflected in the predictive 
margins.  The 95% model estimates margins to be 2.3 mm and 2 mm.  As in most cases, when the 99% criteria 
is applied there is an increase in the margins to 2.8 mm and 2.5 mm.  These results are slightly less than the 









Table 3.14 Summary of Comparisons between Accepted Clinical Models and the Bayesian Model for the Y-
vector.  Values indicate % of data points falling outside the clinical margins. 
Patient 2 mm 6/4 mm Bayes 95 Bayes 99 
101 .25 0 1.5 .17 
102 5.5 .07 16.1 9.3 
103 2.8 .07 .14 .08 
106 7.7 .01 3 .67 
108 .61 0 0 0 
109 8.9 .08 2.9 .71 
110 8.7 .02 6 3.3 
111 7.1 .03 4.1 1.6 
112 .82 0 .05 0 
113 .39 0 .64 .12 
114 7.4 .78 6.9 4.6 
115 16.9 .16 3.6 1.8 
116 12.8 .22 9.5 4.8 
117 14.4 .57 .52 .32 
118 14.7 .04 5.2 5.1 
119 4.5 .65 3.8 3.8 
120 .31 0 .18 .03 
123 14.4 .25 2.3 .59 
124 10.6 .21 18.7 18.7 
125 5.6 .3 1.7 1.2 
126 7.1 .02 7.8 6.2 
129 13.7 .28 7.7 2.3 
130 6.6 .18 3.3 1 





The results of the clinical comparisons for the Y-model show strong similarities with the Polynomial approach.  
There is improvement between the 95% and 99% models n seven patients.  The CFD did not perform well for 
the Y-vector and is not considered an option in modeling motion in the anterior/posterior directions.   
 
A review of the 95% data shows that threee patients were unacceptable.  CCF 102 had 16.1% of the data fall 
outside of the treatment margins.  This result is identical to the Polynomial model.  However, when the 99% 
criteria is applied, CCF 102 falls into the marginal c tegory with 9.3% falling outside of the margins.  CCF 
124 and 131 also were unacceptable when using this approach.  Even with the 99% criteria, they did improve 
from unacceptable.  These results were consistent with the Polynomial model as well for both patients. 
 
A review of the 99% model shows that two patients are unacceptable with respect to the established criteria.  
The results are equivalent to the Polynomial model.  Several patients have a slightly higher rate of data points 
falling outside the margins but  the Bayesian approach has slightly smaller margins averaged over 24 patients 
versus the Polynomial model when using the 95% or 99% data. 
 
3.3.3 Bayesian, Z-model 
The Bayesian Z-model shows comparable motion patterns as seen in the Y-model.  The Polynomial model had 
over 91% of the patients score as acceptable, while the CFD approach had only 70% using the 95% criteria.  
Issues such as rectal gas and bladder fill will pose the same problems with the model accurately predicting 
motion in this direction.  Figures 3.17 and 3.18 represent the Posterior distribution for two of the 24 patients 




Figure 3.17 Posterior Distribution for Patient CCF 119, Z-model 
 
Figure 3.18 Posterior Distribution for Patient CCF 125, Z-model 
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A review of both plots shows that the Z-vector exhibits motion similar to the Y-vector.  The width of the 
posterior distribution is increased in both patients as comapared to the X-vector models.   The Z-vector motion 
can be affected by the same biological processes as the Y-vector.  These processes lead to similar motion 
patterns between the two vectors. 
 
CCF 119 shows a relatively asymmetric pattern of motion that is skewed to the inferior border.  The margins 
as predicted using the 95% criteria are 1.5 mm and 3.1 mm respectively.  When applying the 99% criteria the 
margins are increased to 1.8 mm and 3.6 mm.  The mean argins for the Z-model using the 95% value are 
2.38 mm and 2.54 mm.  The mean increases to 2.86 mm and 3.1 mm when applying the 99% value.  CCF 113 
shows a superior margin well below the mean while te inferior margins are in excess of the patient 
population. 
 
CCF 125 shows a more symetrical pattern over the first five fractions.  This increase is reflected in the
predictive margins.  The 95% model estimates margins to be 3.1 mm and 1.9 mm.  As in most cases, when the 
99% criteria is applied there is an increase in the margins to 3.7 mm and 2.4 mm respectively.  These r ults 
demonstrate margins that are in excess of the mean for the superior direction and less than the mean for the 







Table 3.15 Summary of Comparisons between Accepted Clinical Models and the Bayesian Model for the Z-
vector.  Values indicate % of data points falling outside the clinical margins. 
Patient 2 mm 6/4 mm Bayes 95 Bayes 99 
101 .24 .21 .91 .22 
102 9 .02 5.3 .87 
103 4.3 .02 1.1 .47 
106 15.1 .05 2.9 1.4 
108 1.1 0 .08 .01 
109 6.1 .45 .94 .68 
110 13.3 2.4 8.4 4.8 
111 6.6 .25 11.6 6.4 
112 5.2 0 1.9 .1 
113 .83 .01 3.2 3.2 
114 9.6 .57 9.3 6 
115 17.9 .03 3 .69 
116 16.9 .12 1.4 .4 
117 14.1 .69 1.7 1 
118 8.6 0 2.7 .64 
119 21.2 .09 13.1 8.7 
120 .31 0 .12 0 
123 7.2 .01 3.5 3.3 
124 6 0 6.1 5 
125 10.4 .55 4 2.7 
126 8.2 .03 7.3 5.4 
129 5.7 .02 5.3 3.6 
130 2.4 .54 1.6 1.4 




The results of the clinical comparisons for the Z-model show strong similarities with the Polynomial approach.  
There is improvement between the 95% and 99% models n 23 patients.  The CFD did not perform well for 
the Z-vector and is not considered an option in modeling motion in the superior/inferior motion.   
 
A review of the 95% data shows that threee patients were unacceptable.  CCF 111 had 11.6% of the data fall 
outside of the treatment margins.  This result is larger than seen in the Polynomial model.  However, when the 
99% criterion is applied, CCF 111 falls into the marginal category with 6.4% falling outside of the margins.  
CCF 119 and 131 also were unacceptable using this model.  Even with the 99% criteria, CCF 131 did not fall 
into the acceptable or marginal range.  CCF 119 did move to a marginal score with 8.7%.  These results were 
consistent with the Polynomial model as well for both patients. 
 
A review of the 99% model shows that only one patient was unacceptable with respect to the established 
criteria.  The results are equivalent to the Polynomial model.  CCF 131 was unacceptable across both mdels.  
This result is indicative of a bad data sampling over the first five fractions.  The Bayesian approach has smaller 
margins averaged over 24 patients versus the Polynomial model when using the 95% or 99% data. 
 
3.3.4 Summary of Bayesian Model Results 
The Bayesian approach which incorporates a prior and likelihood function to compute a posterior density is the 
third model developed to predict prostate motion.  The first five fractions are used in determining the posterior 
density.  The Polynomial model was acceptable across the 24 patients except for an unacceptable result in two 
patients.  The CFD did not perform well and is not considered to be a plausible approach to this reseach.   
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A total of 24 patients were modeled with the Polynomial approach.  These same patients were then compared 
directly to the Bayesian approach to see how the models performed based on the same data.  The results show 
that they are the same when comparing the percentage of data points that fall outside of the margins.   In 
general, the Bayesian approach delivered comparable esults with smaller overall margins.  This is significant 
in that the reduced margins will lead to a lower volume of normal tissue irradiation.  In addition, this can 
reduce the risk to secondary cancers.   
 
The X-model followed a similar pattern as seen the Polynomial and CFD approaches.  This pattern is a result 
of a general lack of motion in the lateral direction f r the prostate.  A baseline value of 1.5 mm has been 
chosen as the threshold for the model when smaller margins are predicted.  This is necessary in order to 
account for accuracy of setup and immobilization.  The fact that all three models converged on the lack of 
motion and the results of this approach across the pati nt population support it, a uniform model is most likely 
needed for the X-vector.   
 
The X-model results for the Bayesian model are almost identical to the Polynomial approach.  The only 
difference is that there is one additional patient n the 5-10% range of marginal as opposed to the 0-5% range.  
This is minimal and doesn’t affect the outcomes of the model.  The 1.5 mm margins were determined fromthe 
beginning and it is important to note that those margins might need to be changed when developing a uniform 
clinical model for clinical use.  The reduction of 6 mm to 1.5 mm is clinically significant and should have an 




The results for the Bayesian Y-model show almost identical numbers as the Polynomial model.  This has no 
clinical impact.  As previously mentioned, the results are similar but the margins are generally smaller on the 
Bayesian model as shown in previous tables.  This offers a clinical advantage while still maintaining 
equivalent tumor coverage.  The Bayesian model for the Y-vector appears to be superior to the Polynomial and 
CFD approaches. 
 
The results for the Z-model using the Bayesian approach are mixed when compared to the Polynomial 
approach.  The 99% model is very similar except for a difference in one patient.  The Bayesian 95% does n t 
perform as well by a total of two patients.  The ovrall margins continue to be smaller for the Bayesian Z-
model (i.e. shown in previous tables) and thus make it a better treatment option.  In addition, the possibility of 
introducing an informative prior when enough data is vailable could potentially improve the model in the long 
term. 
 
3.4 Correlation Analysis 
The methods and theory behind the correlation analysis were presented in Chapter 2.  While a full analysis of 
all 24 patients is beyond the scope of this research,  limited analysis of several patients will provide an insight 
into the modeling process.  The primary purpose of correlation analysis is to determine whether the motion of 
the prostate is inter-related to different vector cmponents.  If a particular vector model shows no correlation 





A total of three patients have been chosen to review in this section.  Although two of the patients were chosen 
randomly, one patient was not.  CCF 131 was chosen du  to the fact that all predictive models were 
unacceptable according to accepted criteria.  The correlation on this particular patient would help to determine 
whether there is something unique to that patient or the results are similar to other patients.  The review will be 
based on comparing the first five fractions since the predictive margins are determined with this dataset.  Then, 
there will be a review of the remaining 33 fractions to see if there is a measurable change in the corr lation. 
 
3.4.1 Analysis of Patient Results 
A total of three patients are reviewed for their correlation.  The Pearson coefficient will be the factor that is 
compared between the patients.  In addition, the p-value will be discussed.  Table 3.13 summarizes the results 
for the initial five fractions for each of the three patients presented. 
 
Table 3.16 Summary of Correlation Analysis for First Five Fractions 
  Pearson   p-value  
 X-Y X-Z Y-Z X-Y X-Z Y-Z 
CCF 101 -.16 -.15 .77 0 0 0 
CCF 111 -.38 -.48 .54 0 0 0 





From the three patients shown, the p-value confirms that the results are significant.  In addition, there is a 
negative correlation between the X-vector and Y-vector across all patients.  This result is mixed with respect to 
the X and Z-vector.  CCF 131 shows a positive correlation.  This result is classified as fair per the criteria set 
forth in Chapter 2.  The results do confirm a positive correlation between the Y and Z-vectors across all 
patients.  This supports results presented in Chapter 3.  The lack of correlation with the X-vector supports the 
theory that lateral motion is independent of other motion and the model can be independent.  The results of the 
remaining 34 fractions are presented in Table 3.14. 
 
Table 3.17 Summary of Correlation Analysis for Remaining 34 Fractions 
  Pearson   p-value  
 X-Y X-Z Y-Z X-Y X-Z Y-Z 
CCF 101 .018 -.078 .16 0 0 0 
CCF 111 -.11 .090 .23 0 0 0 
CCF 131 -.024 -.060 .66 0 0 0 
 
 
The results shown above indicate a reduced correlation of motion over all three vectors.  The X-vector still 
indicates little to no correlation between the Y and Z-vectors.  The Y-Z vector shows correlation over all three 
patients but it is not strong except for CCF 131 (Khan, 2012).  The .656 value is an increase over the .273 seen 
in the first five fractions.   
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In general there is not a definitive result from the ree patients reviewed.  There appears to be a lack of 
correlation between the X and the other vector components for all patients.  This is supported in the predictive 
modeling as well.  The correlation between the Y and Z vectors is present but not strong except for CCF 131.  
A qualitative review of the data used for modeling shows this correlation in a number of cases but it is evident 
that this might not be valid for all patients.  Further analysis is warranted in determining the effects of motion 

















Model Implementation and DVH Analysis 
4.0 Model Overview 
The reasoning behind this research is two-fold.  First, it is necessary to determine if prostate motion is 
predictable.  That was accomplished by using several statistical approaches that divided prostate motion into 
three distinct vector models.  A separate model was developed for each vector using the first five fractions of 
data.  The developed margins were then applied to the remaining 33 fractions to determine the effectivness of 
the model.  The results presented in Chapter 3 validate the Bayesian statistical method as the most effective 
model.  The Bayesian approach accurately predicts margins without using too large or too small margins.  The 
second point of this research is that if you develop predictive margins, will it make a clinical difference for the 
patient?  The potential clinical impact is what will change the way radiation therapy is delivered.  This 
approach will reduce the dose to the bladder and rectum while maintaining equivalent dose to the prostate will 
result in less complications and side effects.  In addition, it will reduce the amount of normal tissue irradiated 
during treatment.  This can lead to a reduction in secondary cancers. 
 
4.1 Treatment Planning Process 
As previously discussed, it is necessary to compare the performance of the predictive margins with clini ally 
accepted margins in order to measure the clinical impact.  This was accomplished so that the most direct 
comparison could be made.  The initial step was to take a CT data set from a patient that has been obtained for 
treatment planning.  The CT scan represents a patient who has no distinct anatomical issues and is of average 
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height and weight.  The prostate along with rectum and bladder were contoured by a Board Certified Radiation 
Oncologist.  These contours are then verified by the medical dosimetrist for completeness.   
 
Chapter 3 discusses two clinical models, 2 mm and the 6/4 mm margin.  The results over the group of 24 
patients demonstrate that a 2 mm margin is not clinically acceptable due to the amount of time that the prostate 
exceeds the margins.  Therefore, the model comparison in this section will focus on the 6/4 mm versus the 
Bayesian model.  The Pinnacle treatment planning system was used for all treatment planning on the 24 
patients.  This system is an FDA 510k cleared planning system that is comparable to all other commercial 
treatment planning systems.  Since IMRT is considere  standard of care, it was used as the method of 
treatment delivery in the planning process.   
 
The medical dosimetrist expands the margins around the prostate using the treatment planning algorithm that 
requires the expansion to be done in the (X,Y,Z) direct ons.  The margins are first expanded using the 6/4 mm 
model.  Once those margins are completed, an IMRT plan is developed to deliver a dose of 78 Gy over a 
course of 38 fractions.  This results in a daily dose f 200 cGy.  The IMRT plan is an optimization process that 
is performed by the Pinnacle TPS.  The user inputs criteria at the beginning and the computer then determines 
the best method of delivery.  In order to minimize variations in the plan comparison, all inputted criteria is 
identical for either the standard margins or Bayesian plan. 
 
Once the IMRT plan has been generated, the dosimetrist verifies planning accuracy and clinical acceptability.  
In every case of an inverse optimization plan, there has to be minor adjustments to the plan in order to make it 
clinically acceptable.  This adjustment can be a different weighting to a beam or an optimization parameter.  
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These adjustments are not significant to the overall pl n and do not change the comparison results.  Once the 
plan is considered clinical acceptable, a Dose Volume Histogram (DVH) is generated for analysis.  For the 
purpose of this research, the DVH includes dose to the bladder and rectum.  This process is then duplicated 
with the only difference being the predictive margins as determined by the Bayesian model.   
 
The DVH is analyzed at varying dose levels in order to quantify the reduction across high, mid and lowlevels 
of dose.  The 70 Gy threshold is considered the high dose value that has impact with complications such as 
rectal bleeding and late term complications.  The 50 Gy dose is the mid level dose used and is an indicator of 
potential late term complications.  The lower thresold is the 20 Gy value.  Although low levels of dose are not 
as critical to acute reactions, they are a concern for secondary cancers and overall late term effects.   
 
4.2 DVH Analysis 
The 6/4 mm margin plan will be referred to as the base plan.  The base plan is what is considered stanard of 
care for patients being treated with the Calypso system in current radiation oncology practices.  Once the 
IMRT plan has been generated using the base plan margins, the generated DVH will be used as the basis for 
comparison against the 24 research patients.  The bas  plan is represented by the solid line.  The Bayesi n 
IMRT plan is represented by dashed lines.   Figure 4.1 and 4.2 show sample DVH comparison graphs.   The






Figure 4.1 DVH for Patient CCF 101 
 
Figure 4.2 DVH for Patient CCF 130 
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The figures above give a visual aspect to the volume reduction when incorporating predictive margins.  Both 
patient CCF 101 and 130 show volume reductions across the range of doses for both the rectum and bladder.  
The rectum is colored in brown and the bladder in burnet orange.  Table 4.1 gives the DVH values associated 
with the rectal bladder doses as calculated when using the base plan. 
 
Table 4.1 Base Plan Showing % Volume Receiving Given Dose 
 70 Gy 50 Gy 20 Gy 
Rectum 4.1 9.88 33.25 
Bladder 5.35 9.27 20.97 
 
 
The DVH values listed in Table 4.1 are exclusive to the anatomy and plan developed for the specific patient in 
this research.  The doses are considered a baseline with which the Bayesian model will be compared against.  
To see the full table of DVH data for each patient please refer to the Appendix for further information.  In 
order to simplify the results, each patient will be listed with the corresponding % reduction in volume for each 







Table 4.2 Summary of % volume reduction for all 24 patients in comparison to the base plan  
Patient  Rectum   Bladder  
 70 Gy 50 Gy 20 Gy 70 Gy 50 Gy 20 Gy 
101 17.8 14.7 13.1 48.8 45.2 38.6 
102 27.3 47.1 7.8 46.9 10.2 32.3 
103 0 2.8 14.7 43.9 38.5 27 
106 63.2 14.7 13.1 70.8 62 41.2 
108 36.6 25.1 2.7 18.7 21.2 9.9 
109 26.8 19 10.2 50.1 43.1 34.9 
110 48.8 36.6 32.8 46.3 42.8 37.5 
111 21 23.4 32.8 57.1 49.2 40.7 
112 36.6 30.2 25.3 53.4 47.1 41.3 
113 56.8 43 30.4 66.5 59.8 48.6 
114 35.4 25.7 62.3 54.6 47.5 23.5 
115 37.8 31 25.3 53.1 46.8 40.8 
116 24.4 20.1 27.4 53.4 46.8 41.3 
117 4.9 10.7 22.6 48.9 42.7 40 
118 26.8 24.1 23.2 60 52.5 43.7 
119 21.2 23.7 24.4 55.7 48.5 42.3 
120 34.1 29.1 25.3 53.3 47.3 42.3 
123 27.3 24.5 23.8 58.7 51.3 43.7 
124 37.8 30.2 25.3 58.7 51.4 42.8 
125 29.3 26.1 25.3 49.5 44.4 41.3 
126 24.4 25.1 25 54.9 48.2 42.3 
129 19.5 23.1 22.3 54.8 48.2 42.8 
130 29.3 26.1 24.7 52.5 46.5 42.3 
131 44.9 33.1 20.8 55.7 49.6 41.3 
Mean 




Table 4.2 shows a significant reduction in dose to a given volume over the full range of 24 patients.  Based on 
the Bayesian predictive margins, there is an average volume reduction of 30.5% receiving 70 Gy for the 
rectum.  This is followed by slightly smaller reduction for the 50 and 20 Gy values.  All patients realized a 
reduced volume except for CCF 103.   In that instance, the predictive margins did not reduce the high dose 
region but did show minimal volume reduction across ther dose levels.  The volume reduction for the rectal 
doses will have a significant clinical impact on patients.  This reduction will lead to less acute complications 
while reducing the potential for late term effects, including secondary cancers. 
 
The volume reduction with regards to the bladder is larger than the rectal values.  This is due to the location of 
the anterior rectal wall with relation to the prostate.  The bladder when filled, will push more of the organ out 
of the field and thus have a potential for greater volume reduction.  Over the 24 patients, the average volume 
reduction for the 70 Gy dose is 52.8%.  Patient CCF 106 had a reduction in excess of 70%.  Only one pati nt 
had less than 40% reduction, CCF 108.  The mid and low dose ranges also had measured reduction in volumes.   
 
In summary, there is large reduction in the rectal and bladder volumes receiving dose across all patients.  The 
use of predictive margins reduces the risk of acute and late term complications.  In addition, the reduction in 










This research has focused on three approaches to developing a method that will accurately predict treament 
margins for prostate cancer patients.  Developing predictive margins allows for less normal tissue to be 
irradiated and reduces the overall risk for secondary c ncers.  There is growing interest in the oncology 
community to reduce radiation dose whether it is through diagnostic or therapeutic procedures.  Currently all 
patients are treated with uniform margins (Van Herk, 2000).  
 
5.1 The Polynomial Model 
The initial model was an 8th order polynomial.  The 95% and 99% predictive lines were applied to the first five 
fractions and the resulting margins were used for clinical purposes.  These margins were then analyzed against 
the remaining 34 fractions to determine if the model was acceptable, marginal or unacceptable.  The 
Polynomial model performed well based on the results.  The X-model scored acceptable in 21 of the 24 
patients.  A threshold of 1.5 mm was applied when the model indicated small margins that would not be 
clinically deliverable.  The Y-model had similar results as well.  When using the 99% criteria, a total f 19 
patients had acceptable results.  There were only three unacceptable results out of the 24 patients.  The Z-
model showed satisfactory results as well.  A total f 20 patients scored acceptably with only three patients 
scoring unacceptably.  The unacceptable results in both the Y-model and Z-model are direct results of patients 
not showing similar motion patterns in the first five fractions versus the remaining fractions.  Suggestions on 
how to deal with this issue will be presented later.  The Polynomial is an acceptable model for predictive 
99 
 
margins.  The vast majority of patients performed well and the resulting predictive margins lead to greatly 
reduced volumes of normal tissue that needs to be treated. 
 
5.2 The CFD Model 
The CFD approach did not result in acceptable margins.  It was initially thought that using the actual d ta, 
might lead to better estimates.  This simplified stati ical method did not function well over the patien  
population.  The results for the X-model matched the Polynomial approach due to the model threshold being 
implemented in the vast majority of cases.  The Y-model at had 10 patients score in the acceptable range when 
using the 99% criteria.  This is not acceptable for clinical implementation.  The Z-model scored slightly better 
in that 15 patients scored acceptably when using the 99% model.  Overall the CFD model appears to be 
insufficient in developing patient specific margins.  It is not recommended for patient treatment. 
 
5.3 The Bayesian Model 
The third model developed was the Bayesian approach.  The posterior density is calculated using a likelihood 
function and a prior.  Since the majority of prostate motion follows a Gaussian distribution (Khan, 2008), it 
was used as the likelihood function.  For the purposes of this research, a uniform prior was implemented.  The 
Bayesian model appears to be very effective at modeling prostate motion.  The X-model results match that of 
the Polynomial as well as CFD approaches.  Based on the results of this research, a uniform X-model is 
recommended across all patients.  There is a lack of motion in the lateral directions and the motion that is 
present is minimal.  These results indicate that uniform margins at significantly reduced sizes can be 
effectively utilized as acceptable clinical margins.  The Y-model matches the results of the Polynomial 
approach.  A total of 19 patients scored acceptable results using the 99% criteria.  The main difference between 
100 
 
the Polynomial and Bayesian methods is that the Bayesi n model had equal results with margins that were 
smaller.  This will result in a direct clinical advantage to the patient over the course of treatment.  The 
performance of the Z-model was slightly less than the Polynomial approach.  A total of 19 patients had
acceptable results.   Although it resulted in one less patient having acceptable results, the overall margin 
reduction between the two models makes the Bayesian approach more effective from a clinical perspective.   
 
Based on the results of this research, the Bayesian model is the best approach to develop patient specific 
treatment margins for prostate cancer.  A balance between too small and too large of margins is accomplished 
with the posterior density.  Through proper data colle tion, modeling and implementation, predictive margins 
can greatly reduce dose to normal tissue and reduce the risks associated with secondary cancers. 
 
5.4 DVH Summary 
The Bayesian model has shown the best results with minimal margins in predicting prostate motion across the 
population of 24 patients.  The ability to model the motion is alone not sufficient to determine the clinical 
efficacy of this model.  The DVH was generated across all 24 patients in order to compare the clinical results 
of a standard 6/4 mm model versus the predictive margins as determined by the Bayesian method. 
 
There is significant reduction in irradiated volume across all dose levels for both the rectum and blader.  This 
is accomplished while maintaining equivalent dose to the prostate gland itself.  All patients realized a ose 
reduction with their associated predictive margins.  The amount of reduction was more than anticipated nd 
indicates that this approach will have a substantial clinical impact.  In addition to reducing dose to critical 
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structures, there is a potential to allow for dose e calation to the prostate while maintaining acceptable dose to 















Future Work  
6.0 Areas for Additional Work 
The scope of this research was to determine whether prostate motion was patient specific or uniform across a 
population.  If specific, then could it be modeled?  Those questions were answered along with an in-depth 
analysis.  However, there are additional areas that can be researched going forward that can greatly enhance 
the findings of this research. 
 
The first area of additional work involves the determination of appropriate margins for the X-vector.  This 
research has shown that the X-model is independent of the other models and is uniform across the population.  
A 1.5 mm margin was assumed for this paper.  However, more analysis should be done going forward in order 
to determine what the optimal margins are for this type of motion.   
 
Another area of interest would be to investigate in more detail why some patients had unacceptable results 
using this approach.  For the X-model, a 1.5 mm margin was used as the threshold.  It might be possible to 
establish similar thresholds for the Y and Z-vectors.  These thresholds would be larger than the 1.5 mm but 
would reduce the effect of a bad data sampling, that results in the poor performance of the model.  The basis 




The data obtained for this study was through the Cleveland Clinic.  Their work was done in close collaboration 
with the manufacturer Calypso.  A multi-institutional study would greatly enhance the research by comparing 
the impact of patient setup, operational limits andgreater population diversity to further validate th se results 
as well as potentially offer areas for model improvement.  
 
The most important area for future development would be to apply an informative prior to the posterior 
distribution in order to determine its impact on margins and clinical efficacy.  This research assumed a non-
informative prior.  There is enough evidence to suggest that a well thought out informative prior based on 
previous patient data or even possibly modeled data can lead to better margin prediction.  Additional p tient 
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Coefficients for the Polynomial approach, X-model. 
 
Patient A0 A1 A2 A3 A4 A5 A6 A7 A8 
101 -4.6 E-3 2.4 E-4 -6.8 E-6 3.4 E-8 6.7 E-11 -9.5 E-13 2.8 E-15 1.7 E-21 0.06 
102 -5.9 E-3 1.2 E-4 -2.8 E-5 3.9 E-7 -2.4 E-9 8.1 E-12 -1.5 E-14 1.3 E-17 -4.9 E-21 
103 3.7 E-3 5.7 E-6 1.1 E-5 -2.1 E-7 1.6 E-9 -6.3 E-12 1.2 E-14 4.7 E-21 .08 
106 -5.2 E-3 7 E-4 2.7 E-5 -2.1 E-9 9.4 E-12 -2.4 E-14 3.1 E-17 -1.7 E-20 .38 
108 .014 -2.1 E-3 3.4 E-5 -2.7 E-7 1.3 E-9 -3.4 E-12 5.5 E-15 -4.7 E-18 1.7 E-21 
109 -.01 -1.4 E-3 3.7 E-5 -4.9 E-7 3.5 E-9 -1.4 E-11 3.2 E-14 -3.7 E-17 1.8 E-20 
110 -1.1 E-3 -4.1 E-4 1.2 E-5 -7.8 E-8 9 E-11 3.4 E-13 6.6 E-16 -6.2 E-18 7.7 E-21 
111 7.5 E-3 -3.3 E-4 -5.8 E-7 7.7 E-8 -6.8 E-10 2.6 E-12 -5.1 E-15 4.9 E-18 -1.9 E-21 
112 6.1 E-3 5.3 E-4 -1.7 E-5 1.9 E-7 -7.6 E-10 2.5 E-13 6.2 E-15 -1.6 E-17 1.2 E-20 
113 -5.3 E-3 1.2 E-3 -2.3 E-5 2 E-7 -8.8 E-10 2 E-12 -2.4 E-15 1.3 E-18 -2.4 E-22 
114 5.9 E-3 -1 E-4 9 E-6 -1.3 E-7 1.1 E-9 -5 E-12 1.3 E-14 -1.9 E-17 1 E-20 
115 -8.6 E-4 -2 E-4 1.2 E-5 -2.4 E-7 2.5 E-9 -1.4 E-11 4.2 E-14 -6.5 E-17 4 E-20 
116 6.5 E-3 1.8 E-5 2.1 E-5 -3.1 E-7 2.1 E-9 -7.5 E-12 1.5 E-14 -1.6 E-17 6.5 E-21 
117 -7.6 E-3 8.7 E-4 -3.5 E-5 5.5 E-7 -4.2 E-9 1.7 E-11 -4 E-14 4.7 E-17 -2.2 E-20 
118 -5.5 E-3 9.5 E-4 -2 E-5 2.1 E-7 -6.1 E-10 -3.2 E-12 2.5 E-14 -5.9 E-17 4.7 E-20 
119 2.7 E-3 7.3 E-4 -1.4 E-5 1.7 E-7 -1.1 E-9 3.8 E-12 -6.9 E-15 6.3 E-18 -2.3 E-21 
120 -2.8 E-3 -4.7 E-4 7.6 E-6 -5.3 E-8 2.9 E-10 -1.4 E-12 4.1 E-15 -5.7 E-18 3.1 E-21 
123 5.6 E-3 -1.3 E-4 1.3 E-5 -2.1 E-7 1.5 E-9 -5.3 E-12 1 E-14 -9.6 E-18 3.6 E-21 
124 -4.6 E-3 2.4 E-4 -1.6 E-5 3.9 E-7 -4.5 E-9 2.8 E-11 -9.9 E-14 1.8 E-16 -1.3 E-19 
125 6 E-3 -4.5 E-4 1.5 E-5 -1.5 E-7 6.8 E-10 -1.6 E-12 1.8 E-15 -8 E-19 -1.8 E-23 
126 -6.4 E-3 4.3 E-4 -3.1 E-5 4.8 E-7 -3.2 E-9 1.1 E-11 -2.1 E-14 2 E-17 -7.8 E-21 
129 -7.1 E-3 5 E-4 -1.6 E-5 1.9 E-7 -1.1 E-9 3.6 E-12 -6.6 E-15 6.3 E-18 -2.4 E-21 
130 -7.4 E-4 1.6 E-4 1.1 E-6 -3.7 E-8 3.1 E-10 -1.3 E-12 2.9 E-15 -3.2 E-18 1.4 E-21 




Coefficients for the Polynomial approach, Y-model. 
 
Patient A0 A1 A2 A3 A4 A5 A6 A7 A8 
101 0 2.7 E-3 -5.8 E-5 6.1 E-7 -3.8 E-9 1.4 E-11 -2.9 E-14 3.1 E-17 -1.3 E-20 
102 0 8.8 E-4 -2.9 E-5 3.6 E-7 -2.3 E-9 8 E-12 -1.5 E-14 1.4 E-17 -4.7 E-21 
103 0 1.2 E-3 -1.4 E-6 -1.6 E-7 1.9 E-9 -8.3 E-12 1.9 E-14 -2.1 E-17 9.2 E-21 
106 0 6.6 E-4 -3 E-5 6.2 E-7 -6.8 E-9 3.8 E-11 -1.1 E-13 1.6 E-16 -9.3 E-20 
108 0 -1.3 E-3 2.5 E-5 -2.7 E-7 1.7 E-9 -6.2 E-12 1.2 E-14 -1.2 E-17 5 E-21 
109 0 1.2 E-3 -4.5 E-5 6.9 E-7 -4.7 E-9 1.7 E-11 -3.1 E-14 2.7 E-17 -8.7 E-21 
110 0 -1.2 E-4 7.4 E-5 -1.2 E-6 9.4 E-9 -4 E-11 9.8 E-14 -1.3 E-16 7.3 E-
200 
111 0 -1.9 E-3 5.4 E-5 -6.2 E-7 3.3 E-9 -9.9 E-12 1.7 E-14 -1.5 E-17 5.6 E-21 
112 0 4.2 E-3 -5.3 E-5 -5.3 E-7 1.3 E-8 -8.1 E-11 2.5 E-13 -3.8 E-16 2.3 E-19 
113 0 -2.1 E-3 6 E-5 -6.6 E-7 3.7 E-9 -1.1 E-11 2 E-14 -1.8 E-17 6.7 E-21 
114 0 -6.4 E-4 8.4 E-5 -2.2 E-6 2.5 E-8 -1.5 E-10 4.5 E-13 -7 E-16 4.4 E-19 
115 0 -1.2 E-3 4.9 E-5 -1.1 E-6 1 E-8 -5.4 E-11 1.6 E-13 -2.3 E-16 1.4 E-19 
116 0 5.8 E-4 6.8 E-6 -1.5 E-7 6.6 E-10 -7.7 E-13 -1.4 E-15 3.8 E-18 -2.3 E-21 
117 0 2.1 E-3 -1.8 E-4 3.7 E-6 -3.1 E-8 1.3 E-10 -3 E-13 3.5 E-16 -1.6 E-19 
118 0 -2.9 E-3 1.5 E-4 -2.9 E-6 2.6 E-8 -1.3 E-10 3.6 E-13 -5.1 E-16 3 E-19 
119 0 -2.3 E-4 1.6 E-5 -2 E-7 1 E-9 -2.7 E-12 3.7 E-15 -2.5 E-18 6.4 E-22 
120 0 6.6 E-4 -4.6 E-6 -1.3 E-7 2.2 E-9 -1.2 E-11 3.5 E-14 -4.7 E-17 2.5 E-20 
123 0 1.2 E-3 -2.5 E-6 -1.4 E-7 1.4 E-9 -5.5 E-12 1.2 E-14 -1.3 E-17 5.8 E-21 
124 0 -1.5 E-3 6.3 E-5 -1.4 E-6 1.5 E-8 -9 E-11 2.9 E-13 -4.9 E-16 3.4 E-19 
125 0 -6 E-4 1.1 E-5 -5.3 E-8 -6.6 E-11 1.1 E-12 -3.2 E-15 3.5 E-18 1.4 E-21 
126 0 -6.2 E-4 8.3 E-6 -5.4 E-8 9.3 E-11 4.6 E-13 -2.4 E-15 3.9 E-18 -2.2 E-21 
129 0 7.8 E-4 -3.3 E-5 4.5 E-7 -2.8 E-9 9 E-12 -1.6 E-14 1.5 E-17 -5.7 E-21 
130 0 1.9 E-3 -3.3 E-5 2.2 E-7 -5.5 E-10 -5.2 E-13 4.7 E-15 -7.6 E-18 3.9 E-21 




Coefficients for the Polynomial approach, Z-model. 
 
Patient A0 A1 A2 A3 A4 A5 A6 A7 A8 
101 0 1.6 E-3 3.5 E-6 -2.6 E-7 1.7 E-9 -4.7 E-12 5.5 E-15 -1.9 E-18 -5.9 E-22 
102 0 6.4 E-4 -5.4 E-7 -3.6 E-7 4.6 E-9 -2.5 E-11 6.7 E-14 -9 E-17 4.8 E-20 
103 0 8.3 E-4 5.2 E-6 -2.4 E-7 2.3 E-9 -1 E-11 2.3 E-14 -2.5 E-17 1.1 E-20 
106 0 -2.7 E-3 7.3 E-5 -6.9 E-7 1.6 E-9 8.6 E-12 -5.5 E-14 1.1 E-16 -7 E-20 
108 0 6.4 E-5 4.2 E-6 -1 E-7 8.9 E-10 -3.5 E-12 7 E-15 -7.1 E-18 2.8 E-21 
109 0 -1.1 E-3 -4.9 E-6 3.5 E-7 -3.3 E-9 1.3 E-11 -2.8 E-14 2.7 E-17 -9.4 E-21 
110 0 -1.2 E-3 6.5 E-5 -1 E-6 7.9 E-9 -3.4 E-11 8.3 E-14 -1.1 E-16 5.9 E-20 
111 0 6.3 E-4 -2.3 E-6 -8.6 E-8 8.1 E-10 -3 E-12 5.8 E-15 -5.5 E-18 2.1 E-21 
112 0 9.8 E-3 -2 E-4 9.5 E-7 4.4 E-9 -5.4 E-11 1.9 E-13 -2.9 E-16 1.7 E-19 
113 0 1 E-4 7.5 E-8 1.9 E-8 -2.1 E-10 8.5 E-13 -1.6 E-15 1.5 E-18 -5.3 E-22 
114 0 3.4 E-3 -5.4 E-5 -1.8 E-7 8 E-9 -6 E-11 2.1 E-13 -3.5 E-16 2.3 E-19 
115 0 -7.2 E-4 2 E-5 -6.8 E-7 8.1 E-9 -4.6 E-11 1.4 E-13 -2.2 E-16 1.3 E-19 
116 0 -4.6 E-3 1.5 E-4 -1.9 E-6 1.1 E-8 -3.8 E-11 6.9 E-14 -6.7 E-17 2.6 E-20 
117 0 2.6 E-3 -1.4 E-4 2.7 E-6 -2.1 E-8 8.6 E-11 -1.8 E-13 2 E-16 -8.7 E-20 
118 0 -1.3 E-3 6.3 E-5 -1.3 E-6 1.2 E-8 -5.2 E-11 1.1 E-13 -1.2 E-16 4.6 E-20 
119 0 -1 E-3 5.70E -5 -9.40E-7 6.3 E-9 -2.1 E-11 3.8 E-14 -3.5 E-17 1.3 E-20 
120 0 -1.3 E-3 2.5 E-5 -3.2 E-7 2.3 E-9 -9.2 E-12 2 E-14 -2.3 E-17 1 E-20 
123 0 -1.5 E-4 5.4 E-6 -1.6 E-7 1.4 E-9 -5.8 E-12 1.3 E-14 -1.4 E-17 6.4 E-21 
124 0 1.4 E-3 -5.7 E-5 8.6 E-7 -7.9 E-9 4.6 E-11 -1.6 E-13 3 E-16 -2.3 E-19 
125 0 -4.1 E-4 2.1 E-5 -2.7 E-7 1.6 E-9 -4.8 E-12 7.4 E-15 -5.8 E-18 1.7 E-21 
126 0 1..1 E-3 -2.5 E-5 1.7 E-7 -2.9 E-10 -1 E-12 4.8 E-15 -7 E-18 3.4 E-21 
129 0 -2.6 E-4 -8.4 E-6 1.6 E-7 -1.1 E-9 4 E-12 -7.7 E-15 7.4 E-18 -2.8 E-21 
130 0 2 E-3 -7.5 E-5 10 E-7 -6.1 E-9 1.9 E-11 -3.4 E-14 3.1 E-17 -1.1 E-20 



















Bayesian Parameters for X-model 
 
Patient Mean Variance St Dev. 
101 -.007 .0011 .033 
102 -.085 .0059 .077 
103 .018 .0034 .058 
106 -.00073 .00071 .027 
108 -.012 .0064 .08 
109 .0074 .021 .14 
110 .012 .003 .055 
111 -.029 .0037 .061 
112 .061 .021 .14 
113 .019 .007 .09 
114 .02 .0078 .088 
115 -.0033 .00076 .027 
116 .04 .002 .045 
117 .019 .027 .16 
118 .03 .0008 .028 
119 -.017 .003 .056 
120 -.015 .00038 .019 
123 -.087 .005 .071 
124 -.019 .0012 .035 
125 .032 .0015 .038 
126 -.035 .0047 .069 
129 .003 .0009 .03 
130 .017 .002 .044 





Bayesian Parameters for Y-model 
 
Patient Mean Variance St Dev. 
101 .003 .009 .097 
102 -.015 .0031 .055 
103 .038 .019 .14 
106 -.069 .0092 .096 
108 .044 .019 .14 
109 .03 .011 .10 
110 .086 .0077 .087 
111 -.077 .008 .09 
112 .011 .009 .097 
113 .015 .0075 .086 
114 .015 .0075 .086 
115 -.0033 .00076 .027 
116 -.085 .0079 .089 
117 -.013 .052 .23 
118 -.081 .0053 .072 
119 -.037 .003 .055 
120 .031 .0074 .086 
123 -.011 .013 .11 
124 -.04 .0013 .036 
125 .031 .015 .12 
126 -.063 .0049 .07 
129 .028 .0087 .093 
130 -.017 .0095 .097 





Bayesian Parameters for Z-model 
 
Patient Mean Variance St Dev. 
101 .017 .011 .11 
102 -.035 .0064 .08 
103 .0098 .013 .11 
106 -.067 .012 .11 
108 .07 .013 .11 
109 .007 .021 .14 
110 .025 .009 .097 
111 -.03 .004 .061 
112 .06 .021 .15 
113 .02 .008 .09 
114 .02 .008 .09 
115 -.09 .01 .1 
116 -.02 .02 .15 
117 .018 .027 .16 
118 -.09 .008 .089 
119 -.03 .015 .12 
120 -.018 .015 .12 
123 -.087 .005 .07 
124 -.056 .004 .063 
125 .061 .01 .1 
126 -.03 .005 .069 
129 -.045 .005 .071 
130 -.03 .013 .11 
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